Note: Descriptions are shown in the official language in which they were submitted.
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 1 -
POLYPEPTIDES HAVING BRANCHING ENZYME ACTIVITY
AND NUCLEIC ACIDS ENCODING SAME
Background of the Invention
Field of the Invention
The present invention relates to isolated polypeptides
having branching enzyme activity and isolated nucleic acid
sequences encoding the polypeptides. The invention also relates
to nucleic acid constructs, vectors, and host cells comprising
the nucleic acid sequences as well as methods for producing and
using the polypeptides.
Description of the Related Art
Branching enzyme (EC 2.4.1.18) hereinafter denoted BE,
catalyzes transglycosylation to form the alpha-1,6-glucosidic
linkages (branch points) of glycogen and amylopectin in
microorganisms, plants and higher organisms. Glycogen and
amylopectin are highly branched starch materials used for
energy storage in microorganisms, plants and higher organisms.
Not only does BE form a branch between different molecules
(intermolecular transfer), it also catalyzes the transfer of a
multi-branched glucan to another site on the same molecule
(intramolecular transfer).
Highly branched starch materials have unique properties
like high solubility, low viscosity and less tendency to
retrograde compared to unmodified starch, which make them
interesting for use in adhesive compositions including surface
sizing and coating in the paper industry as described in EP 0
690 170, food and drink additives and anti-starch
retrogradation agents as described in US 4 454 161.
Branching enzymes from several different organisms have
been isolated and disclosed, e.g.: US 4 454 161 describes a BE
from Bacillus megaterium; Boyer and Preiss, Biochemistry, vol.
16 (16), pp. 3693-3699, 1977, describe a BE from Escherichia
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 2 -
coli; Zevenhuizen, Biochem. Biophys. Acta (81), pp. 608-611,
1964, describes a BE from Arthrobacter globiformis; Walker and
Builder, Fur. J. of Biochem., vol. 20 (1), pp. 14-21, 1971,
describe a BE from Streptococcus mitis; Kiel et al., Gene, vol.
78 (1), pp. 9-18, 1989, describe a BE from the cyanobacterium
Synechococcus sp. PCC7942; Rumbak et al., Journal of
Bacteriology , vol. 173 (21), pp. 6732-6741, 1991, describe a
BE from Butyrivibrio fibrisolvens; Kiel et al., DNA Sequence,
vol. 3 (4), pp. 221-232, 1992, describe a BE from Bacillus
caldolyticus.
A common characteristic of the above mentioned references
is that none of the reported temperature optima are higher than
45 C. Only two branching enzymes have been disclosed which are
characterized by having a higher temperature optimum: Kiel et
al., Molecular & General Genetics, vol. 230 (1-2), pp. 136-144,
1991 (also in EP 0 418 945): a Bacillus stearothermophilus
1503-4R branching enzyme having a temperature optimum of 53 C;
and Takata et al., Applied and Environmental Microbiology, vol.
60 (9), pp. 3096-3104, 1994: a Bacillus stearothermophilus
TRBE14 branching enzyme having a temperature optimum of around
50 C.
Because of the increased reaction rates obtained at higher
temperatures it is industrially advantageous to use branching
enzymes with a high temperature optimum. Thereby a higher
capacity is obtainable with the same amount of enzyme, and a
better production economy is achieved. Furthermore it is
beneficial to run processes at high temperatures due to
prevention of infections.
It is an object of the present invention to provide
improved polypeptides having branching enzyme activity and
nucleic acids encoding the polypeptides.
Summary of the Invention
The present invention relates to isolated polypeptides
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 3 -
having branching enzyme activity, and a temperature optimum of
at least 60 C.
The present invention also relates to isolated nucleic
acid sequences encoding the polypeptides and to nucleic acid
constructs, vectors, and host cells comprising the nucleic acid
sequences as well as methods for producing and using the
polypeptides.
Detailed Description of the Invention
Polypeptides Having Branching Enzyme Activity
"branching enzyme activity" is 1,4-alpha-glucan branching
activity which catalyzes the formation of 1,6-alpha-glucosidic
linkages of glycogen or amylopectin (EC 2.4.1.18). For purposes
of the present invention, branching enzyme activity may be
determined according to the modified version of the procedure
described by Takata et al., Applied and Environmental
Microbiology (1994), p. 3097 (assay A), which is described in
the Materials and Methods section herein under the heading
"Branching enzyme activity".
In a first aspect, the present invention relates to
isolated polypeptides having branching enzyme activity, and
having a temperature optimum of at least 60 C; preferably the
temperature optimum is in the range of 60 C to 120 C; more
preferably the temperature optimum is in the range of 60 C to
100 C; even more preferably the temperature optimum is in the
range of 60 C to 80 C; most preferably the temperature optimum
is in the range of 60 C to 70 C; and even most preferably the
temperature optimum is 65 C.
In a first embodiment, the polypeptides of the present
invention retain about 70% relative activity in the range of pH
6 to pH 8; preferably about 80% relative activity in the range
of pH 6 to pH 7; more preferably the pH optimum is around pH 7.
The conditions used for determining the temperature and pH
optima are those described in the Materials and Methods section
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 4 -
herein under the heading "Branching enzyme activity".
In a second embodiment, the polypeptides of the present
invention have an amino acid sequence which has a degree of
homology to amino acids 2 to 621 of SEQ ID NO:2 (i.e. the
mature polypeptide) or to the amino acid sequence encoded by
the nucleic acid sequence contained in plasmid pT7Blue
contained in E. coli DSM 12607 of at least about 65%,
preferably at least about 70%, more preferably at least about
80%, even more preferably at least about 90%, most preferably
at least about 95%, and even most preferably at least about
97%, which have branching enzyme activity (hereinafter
"homologous polypeptides"). In a preferred embodiment, the
homologous polypeptides have an amino acid sequence which
differs by five amino acids, preferably by four amino acids,
more preferably by three amino acids, even more preferably by
two amino acids, and most preferably by one amino acid from the
amino acid sequence of SEQ ID NO:2.
For purposes of the present invention, alignments of
sequences and calculation of homology scores may be done using
a full Smith-Waterman alignment, useful for both protein and
DNA alignments. The default scoring matrices BLOSUM50 and the
identity matrix are used for protein and DNA alignments
respectively. The penalty for the first residue in a gap is -12
for proteins and -16 for DNA, while the penalty for additional
residues in a gap is -2 for proteins and -4 for DNA. Alignment
may be made with the FASTA package version v20u6 (W. R. Pearson
and D. J. Lipman (1988), "Improved Tools for Biological
Sequence Analysis", PNAS 85:2444-2448, and W. R. Pearson (1990)
"Rapid and Sensitive Sequence Comparison with FASTP and FASTA",
Methods in Enzymology, 183:63-98). Multiple alignments of
protein sequences may be made using "ClustalW" (Thompson, J.D.,
Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through
sequence weighting, positions-specific gap penalties and weight
matrix choice. Nucleic Acids Research, 22:4673-4680). Multiple
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 5 -
a 1 i gnment of DNA sequences may be done using the protein
alignment as a template, replacing the amino acids with the
corresponding codon from the DNA sequence.
Preferably, the polypeptides of the present invention
comprise the amino acid sequence of SEQ ID NO:2 or an allelic
variant thereof; or a fragment thereof that has branching
enzyme activity. In a more preferred embodiment, the
polypeptide of the present invention comprises the amino acid
sequence of SEQ ID NO:2. In another preferred embodiment, the
polypeptide of the present invention consists of the amino acid
sequence of SEQ ID NO:2 or an allelic variant thereof; or a
fragment thereof that has branching enzyme activity. In another
preferred embodiment, the polypeptide of the present invention
consists of the amino acid sequence of SEQ ID NO:2.
A fragment of SEQ ID NO:2 is a polypeptide having one or
more amino acids deleted from the amino and/or carboxyl
terminus of this amino acid sequence.
An allelic variant denotes any of two or more alternative
forms of a gene occupying the same chromosomal locus. Allelic
variation arises naturally through mutation, and may result in
polymorphism within populations. Gene mutations can be silent
(no change in the encoded polypeptide) or may encode
polypeptides having altered amino acid sequences. An allelic
variant of a polypeptide is a polypeptide encoded by an allelic
variant of a gene.
In a third embodiment, the polypeptides of the present
invention have branching enzyme activity which are encoded by
nucleic acid sequences which hybridize under very low
stringency conditions, preferably low stringency conditions,
more preferably medium stringency conditions, more preferably
medium-high stringency conditions, even more preferably high
stringency conditions, and most preferably very high stringency
conditions with a nucleic acid probe which hybridizes under the
same conditions with (i) the nucleotides of SEQ ID NO:1, (ii)
the cDI:A sequence contained in the nucleotides of SEQ ID NO:1,
CA 02367999 2001-09-14
W000/58445
PCT/DK00/00152
- 6 -
(iii) a subsequence of (i) or (ii), or (iv) a complementary
strand of (i), (ii), or (iii) (J. Sambrook, E.F. Fritsch, and
T. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d
edition, Cold Spring Harbor, New York). The subsequence of SEQ
ID NO:1 may be at least 100 nucleotides or preferably at least
200 nucleotides. Moreover, the subsequence may encode a
polypeptide fragment which has branching enzyme activity. The
polypeptides may also be allelic variants or fragments of the
polypeptides that have branching enzyme activity.
The nucleic acid sequence of SEQ ID NO:1 or a subsequence
thereof, as well as the amino acid sequence of SEQ ID NO:2 or a
fragment thereof, may be used to design a nucleic acid probe to
identify and clone DNA encoding polypeptides having branching
enzyme activity from strains of different genera or species
according to methods well known in the art. In particular, such
probes can be used for hybridization with the genomic or cDNA
of the genus or species of interest, following standard
Southern blotting procedures, in order to identify and isolate
the corresponding gene therein. Such probes can be considerably
shorter than the entire sequence, but should be at least 15,
preferably at least 25, and more preferably at least 35
nucleotides in length. Longer probes can also be used. Both DNA
and RNA probes can be used. The probes are typically labeled
for detecting the corresponding gene (for example, with 32P, 3H,
25S, biotin, or avidin). Such probes are encompassed by the
present invention.
Thus, a genomic DNA or cDNA library prepared from such
other organisms may be screened for DNA which hybridizes with
the probes described above and which encodes a polypeptide
having branching enzyme activity. Genomic or other DNA from
such other organisms may be separated by agarose or
polyacrylamide gel electrophoresis, or other separation
techniques. DNA from the libraries or the separated DNA may be
transferred to and immobilized on nitrocellulose or other
suitable carrier material. In order to identify a clone or DNA
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 7 -
which is homologous with SEQ ID NO:1 or a subsequence thereof,
the carrier material is used in a Southern blot. For purposes
of the present invention, hybridization indicates that the
nucleic acid sequence hybridizes to a labeled nucleic acid
probe corresponding to the nucleic acid sequence shown in SEQ
ID NO:?, its complementary strand, or a subsequence thereof,
under very low to very high stringency conditions. Molecules to
which the nucleic acid probe hybridizes under these conditions
are detected using X-ray film.
In a preferred embodiment, the nucleic acid probe is a
nucleic acid sequence which encodes the polypeptide of SEQ ID
NO:2, or a subsequence thereof. In another preferred
embodiment, the nucleic acid probe is SEQ ID NO:?. In another
preferred embodiment, the nucleic acid probe is the nucleic
acid sequence contained in plasmid pT7Blue, which is contained
in Escherichia coli DSM 12607 (see Example 1), wherein the
nucleic acid sequence encodes a polypeptide having branching
enzyme activity.
For long probes of at least 100 nucleotides in length,
very low to very high stringency conditions are defined as
prehybridization and hybridization at 42 C in 5X SSPE, 0.3%
SDS, 200 g/ml sheared and denatured salmon sperm DNA, and
either 25% formamide for very low and low stringencies, 35%
formamide for medium and medium-high stringencies, or 50%
formamide for high and very high stringencies, following
standard Southern blotting procedures.
For long probes of at least 100 nucleotides in length, the
carrier material is finally washed three times each for 15
minutes using 2 x SSC, 0.2% SDS preferably at least at 45 C
(very low stringency), more preferably at least at 50 C (low
stringency), more preferably at least at 55 C (medium
stringency), more preferably at least at 60 C (medium-high
stringency), even more preferably at least at 65 C (high
stringency), and most preferably at least at 70 C (very high
stringency).
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 8 -
For short probes which are about 15 nucleotides to about
70 nucleotides in length, stringency conditions are defined as
prehybridization, hybridization, and washing post-hybridization
at 5 C to 10 C below the calculated Tm using the calculation
according to Bolton and McCarthy (1962, Proceedings of the
National Academy of Sciences USA 48:1390) in 0.9 M NaC1, 0.09 M
Tris-HC1 pH 7.6, 6 mM EDTA, 0.5% NP-40, 1X Denhardt's solution,
1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1
mM ATP, and 0.2 mg of yeast RNA per ml following standard
Southern blotting procedures.
For short probes which are about 15 nucleotides to about
70 nucleotides in length, the carrier material is washed once
in 6X SSC plus 0.1% SDS for 15 minutes and twice each for 15
minutes using 6X SSC at 5 C to 10 C below the calculated Tm.
In a fourth embodiment, the present invention relates to
variants having BE activity of the polypeptide having an amino
acid sequence of SEQ ID NO:2 comprising a substitution,
deletion, and/or insertion of one or more amino acids.
The amino acid sequences of the variant polypeptides may
differ from the amino acid sequence of SEQ ID NO:2 by an
insertion or deletion of one or more amino acid residues and/or
the substitution of one or more amino acid residues by
different amino acid residues. Preferably, amino acid changes
are of a minor nature, that is conservative amino acid
substitutions that do not significantly affect the folding
and/or activity of the protein; small deletions, typically of
one to about 30 amino acids; small amino- or carboxyl-terminal
extensions, such as an amino-terminal methionine residue; a
small linker peptide of up to about 20-25 residues; or a small
extension that facilitates purification by changing net charge
or another function, such as a poly-histidine tract, an
antigenic epitope or a binding domain.
Examples of conservative substitutions are within the
group of basic amino acids (arginine, lysine and histidine),
acidic amino acids (glutamic acid and aspartic acid), polar
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 9 -
amino acids (glutamine and asparagine), hydrophobic amino acids
(leucine, isoleucine and valine), aromatic amino acids
(phenylalanine, tryptophan and tyrosine), and small amino acids
(glycine, alanine, serine, threonine and methionine). Amino
acid substitutions which do not generally alter the specific
activity are known in the art and are described, for example,
by H. Neurath and R.L. Hill, 1979, In, The Proteins, Academic
Press, New York. The most commonly occurring exchanges are
Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn,
Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile,
Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.
In a fifth embodiment, the polypeptides of the present
invention have immunochemical identity or
partial
immunochemical identity to the polypeptide having the amino
acid sequence of SEQ ID NO:2. The immunochemical properties are
determined by immunological cross-reaction identity tests by
the well-known Ouchterlony double immunodiffusion procedure.
Specifically, an antiserum containing polyclonal antibodies
which are immunoreactive or bind to epitopes of the polypeptide
having the amino acid sequence of SEQ ID NO:2 are prepared by
immunizing rabbits (or other rodents) according to the
procedure described by Harboe and Ingild, In N.H. Axelsen, J.
Kroll, and B. Weeks, editors, A Manual of Quantitative
Immunoelectrophoresis, Blackwell Scientific Publications, 1973,
Chapter 23, or Johnstone and Thorpe, Immunochemistry in
Practice, Blackwell Scientific Publications, 1982 (more
specifically pages 27-31). A polypeptide having immunochemical
identity is a polypeptide which reacts with the antiserum in an
identical fashion such as total fusion of precipitates,
identical precipitate morphology, and/or identical
electrobhoretic mobility using a specific immunochemical
technique. A further explanation of immunochemical identity is
described by Axelsen, Bock, and Kroll, In N.H. Axelsen, J.
Kroll, and B. Weeks, editors, A Manual of Quantitative
Immunoelectrophoresis, Blackwell Scientific Publications, 1973,
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 10 -
Chapter 10. A polypeptide having partial immunochemical
identity is a polypeptide which reacts with the antiserum in a
partially identical fashion such as partial fusion of
precipitates, partially identical precipitate morphology,
and/or partially identical electrophoretic mobility using a
specific immunochemical technique. A further explanation of
partial immunochemical identity is described by Bock and
Axelsen, In N.H. Axelsen, J. Kroll, and B. Weeks, editors, A
Manual of Quantitative Immunoelectrophoresis, Blackwell
Scientific Publications, 1973, Chapter 11.
The antibody may also be a monoclonal antibody. Monoclonal
antibodies may be prepared and used, e.g., according to the
methods of E. Harlow and D. Lane, editors, 1988, Antibodies, A
Laboratory Manual, Cold Spring Harbor Press, Cold Spring
Harbor, New York.
The polypeptides of the present invention have at least
20%, preferably at least 40%, more preferably at least 60%,
even more preferably at least 80%, even more preferably at
least 90%, and most preferably at least 100% of the branching
enzyme activity of the polypeptide of SEQ ID NO:2.
A polypeptide of the present invention may be obtained
from microorganisms of any genus. For purposes of the present
invention, the term "obtained from" as used herein in
connection with a given source shall mean that the polypeptide
encoded by the nucleic acid sequence is produced by the source
or by a cell in which the nucleic acid sequence from the source
has been inserted. In a preferred embodiment, the polypeptide
is secreted extracellularly.
A polypeptide of the present invention may be a bacterial
polypeptide. For example, the polypeptide may be a gram
positive bacterial polypeptide such as a Bacillus polypeptide,
e.g., a Bacillus alkalophilus, Bacillus amyloliquefaciens,
Bacillus brevis, Bacillus circulans, Bacillus coagulans,
Bacillus lautus, Bacillus lentus, Bacillus licheniformis,
Bacillus megaterium, Bacillus stearothermophilus, Bacillus
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 11 -
subtilis, or Bacillus thuringiensis polypeptide; or a
Streptomyces polypeptide, e.g., a Streptomyces lividans or
Streptomyces murinus polypeptide; or a gram negative bacterial
polypeptide, e.g., an E. coli or a Pseudomonas sp. polypeptide.
A polypeptide of the present invention may be a fungal
polypeptide, and more preferably a yeast polypeptide such as a
Candida, Kluyveromyces, Pichia,
Saccharomyces,
Schizosaccharomyces, or Yarrowia polypeptide; or more
preferably a filamentous fungal polypeptide such as an
Acremonium, Aspergillus, Aureobasidium, Cryptococcus,
Filibasidium, Fusarium, Humicola, Magnaporthe,
Mucor,
Myceliophthora, Neocallimastix, Neurospora, Paecilomyces,
Penicillium, Piromyces, Schizophyllum,
Talaromyces,
Thermoascus, Thielavia, Tolypocladium, or
Trichoderma
polypeptide.
In a preferred embodiment, the polypeptide is a
Saccharomyces carlsbergensis, Saccharomyces
cerevisiae,
Saccharomyces diastaticus, Saccharomyces
douglasii,
Saccharomyces kluyveri, Saccharomyces norbensis
or
Saccharomyces oviformis polypeptide.
In another preferred embodiment, the polypeptide is an
Aspergillus aculeatus, Aspergillus awamori, Aspergillus
foetidus, Aspergillus japonicus, Aspergillus nidulans,
Aspergillus niger, Aspergillus oryzae, Fusarium bactridioides,
Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum,
Fusarium graminearum, Fusarium graminum, Fusarium heterosporum,
Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum,
Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum,
Fusarium sporotrichioides, Fusarium sulphureum, Fusarium
torulosum, Fusarium trichothecioides, Fusarium venenatum,
Humicola insol ens, Humicola lanuginosa, Mucor
miehei,
Myceliophthora thermophila, Neurospora crassa, Penicillium
purpurogenum, Trichoderma harzianum, Trichoderma koningii,
Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma
viride polypeptide.
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 12 -
In another preferred embodiment, the polypeptide is a
Rhodothermus obamensis, or Rhodothermus marinus polypeptide.
In a more preferred embodiment, the polypeptide is a
Rhodothermus obamensis polypeptide, and most preferably the
polypeptide of coding region of the sequence contained in
plasmid pT7Blue that is contained in Escherichia coli DSM 12607
(see Example 1), e.g., the polypeptide with the amino acid
sequence of SEQ ID NO:2.
It will be understood that for the aforementioned species,
the invention encompasses both the perfect and imperfect
states, and other taxonomic equivalents, e.g., anamorphs,
regardless of the species name by which they are known. Those
skilled in the art will readily recognize the identity of
appropriate equivalents. For example, taxonomic equivalents of
Rhodothermus obamensis are defined by Sako et al.,
International Journal of Systematic Bacteriology , Vol. 46 (4 )
pp. 1099-1104 (1996).
Strains of these species are readily accessible to the
public in a number of culture collections, such as the American
Type Culture Collection (ATCC), Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH (DSMZ), Japan Collection
of Microorganisms (JCM), Centraalbureau Voor Schimmelcultures
(CBS), and Agricultural Research Service Patent Culture
Collection, Northern Regional Research Center (NRRL).
Furthermore, such polypeptides may be identified and
obtained from other sources including microorganisms isolated
from nature (e.g., soil, composts, water, etc.) using the
above-mentioned probes. Techniques for isolating microorganisms
from natural habitats are well known in the art. The nucleic
acid sequence may then be derived by similarly screening a
genomic or cDNA library of another microorganism. Once a
nucleic acid sequence encoding a polypeptide has been detected
with the probe(s), the sequence may be isolated or cloned by
utilizing techniques which are known to those of ordinary skill
in the art (see, e.g., Sambrook et al., 1989, supra).
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 13 -
As defined herein, an "isolated" polypeptide is a
polypeptide which is essentially free of other non-branching
enzyme polypeptides, e.g., at least about 20% pure, preferably
at least about 40% pure, more preferably about 60% pure, even
more preferably about 80% pure, most preferably about 90% pure,
and even most preferably about 95% pure, as determined by SDS-
PAGE.
Polypeptides encoded by nucleic acid sequences of the
present invention also include fused polypeptides or cleavable
fusion polypeptides in which another polypeptide is fused at
the N-terminus or the C-terminus of the polypeptide or fragment
thereof. A fused polypeptide is produced by fusing a nucleic
acid sequence (or a portion thereof) encoding another
polypeptide to a nucleic acid sequence (or a portion thereof)
of the present invention. Techniques for producing fusion
polypeptides are known in the art, and include ligating the
coding sequences encoding the polypeptides so that they are in
frame and that expression of the fused polypeptide is under
control of the same promoter(s) and terminator.
Nucleic Acid Sequences
The present invention also relates to isolated nucleic
acid sequences which encode a polypeptide of the present
invention. In a preferred embodiment, the nucleic acid sequence
is set forth in SEQ ID NO:1. In another more preferred
embodiment, the nucleic acid sequence is the sequence contained
in plasmid pT7Blue that is contained in Escherichia coli DSM
12607 (see Example 1). The present invention also encompasses
nucleic acid sequences which encode a polypeptide having the
amino acid sequence of SEQ ID NO:2, which differ from SEQ ID
NO:1 by virtue of the degeneracy of the genetic code. The
present invention also relates to subsequences of SEQ ID NO:1
which encode fragments of SEQ ID NO:2 that have branching
enzyme activity.
A subsequence of SEQ ID NO:1 is a nucleic acid sequence
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 14 -
encompassed by SEQ ID NO:1 except that one or more nucleotides
from the 5' and/or 3' end have been deleted.
The present invention also relates to mutant nucleic acid
sequences comprising at least one mutation in the polypeptide
coding sequence of SEQ ID NO:1, in which the mutant nucleic
acid sequence encodes a polypeptide which consists of the amino
acid sequence of SEQ ID NO:2.
The techniques used to isolate or clone a nucleic acid
sequence encoding a polypeptide are known in the art and
include isolation from genomic DNA, preparation from cDNA, or a
combination thereof. The cloning of the nucleic acid sequences
of the present invention from such genomic DNA can be effected,
e.g., by using the well known polymerase chain reaction (PCR)
as shown in Example 1, or antibody screening of expression
libraries to detect cloned DNA fragments with shared structural
features. See, e.g., Innis et al., 1990, PCR: A Guide to
Methods and Application, Academic Press, New York. Other
nucleic acid amplification procedures such as ligase chain
reaction (LCR), ligated activated transcription (LAT) and
nucleic acid sequence-based amplification (NASBA) may be used.
The nucleic acid sequence may be cloned from a strain of
Rhodothermus, or another or related organism and thus, for
example, may be an allelic or species variant of the
polypeptide encoding region of the nucleic acid sequence.
The term "isolated nucleic acid sequence" as used herein
refers to a nucleic acid sequence which is essentially free of
other nucleic acid sequences, e.g., at least about 20% pure,
preferably at least about 40% pure, more preferably at least
about 60% pure, even more preferably at least about 80% pure,
and most preferably at least about 90% pure as determined by
agarose electrophoresis. For example, an isolated nucleic acid
sequence can be obtained by standard cloning procedures used in
genetic engineering to relocate the nucleic acid sequence from
its natural location to a different site where it will be
reproduced. The cloning procedures may involve excision and
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 15 -
isolation of a desired nucleic acid fragment comprising the
nucleic acid sequence encoding the polypeptide, insertion of
the fragment into a vector molecule, and incorporation of the
recombinant vector into a host cell where multiple copies or
clones of the nucleic acid sequence will be replicated. The
nucleic acid sequence may be of genomic, cDNA, RNA,
semisynthetic, synthetic origin, or any combinations thereof.
The present invention also relates to nucleic acid
sequences which have a degree of homology to the mature
polypeptide coding sequence of SEQ ID NO:1 (i.e. nucleotides 4
to 1863) of at least about 65%, preferably about 70%,
preferably about 80%, more preferably about 90%, even more
preferably about 95%, and most preferably about 97% homology,
which encode an active polypeptide. For purposes of the present
invention, the degree of homology between two nucleic acid
sequences is determined using a full Smith-Waterman alignment,
useful for both protein and DNA alignments. The default scoring
matrices BLOSUM50 and the identity matrix are used for protein
and DNA alignments respectively. The penalty for the first
residue in a gap is -12 for proteins and -16 for DNA, while the
penalty for additional residues in a gap is -2 for proteins and
-4 for DNA. Alignment is from the FASTA package version v20u6
(W. R. Pearson and D. J. Lipman (1988), "Improved Tools for
Biological Sequence Analysis", PNAS 85:2444-2448, and W. R.
Pearson (1990) "Rapid and Sensitive Sequence Comparison with
FASTP and FASTA" Methods in Enzymology 183:63-98).
Modification of a nucleic acid sequence encoding a
polypeptide of the present invention may be necessary for the
synthesis of polypeptides substantially similar to the
polypeptide. The term "substantially similar" to the
polypeptide refers to non-naturally occurring forms of the
polypeptide. These polypeptides may differ in some engineered
way from the polypeptide isolated from its native source, e.g.,
variants that differ in specific activity, thermostability, pH
optimum, or the like. The variant sequence may be constructed
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 16 -
on the basis of the nucleic acid sequence presented as the
polypeptide encoding part of SEQ ID NO:1, e.g., a subsequence
thereof, and/or by introduction of nucleotide substitutions
which do not give rise to another amino acid sequence of the
polypeptide encoded by the nucleic acid sequence, but which
correspond to the codon usage of the host organism intended for
production of the enzyme, or by introduction of nucleotide
substitutions which may give rise to a different amino acid
sequence. For a general description of nucleotide substitution,
see, e.g., Ford et al., 1991, Protein Expression and
Purification 2: 95-107.
It will be apparent =to those skilled in the art that such
substitutions can be made outside the regions critical to the
function of the molecule and still result in an active
polypeptide. Amino acid residues essential to the activity of
the polypeptide encoded by the isolated nucleic acid sequence
of the invention, and therefore preferably not subject to
substitution, may be identified according to procedures known
in the art, such as site-directed mutagenesis or alanine-
scanning mutagenesis (see, e.g., Cunningham and Wells, 1989,
Science 244: 1081-1085). In the latter technique, mutations are
introduced at every positively charged residue in the molecule,
and the resultant mutant molecules are tested for branching
enzyme activity to identify amino acid residues that are
critical to the activity of the molecule. Sites of substrate-
enzyme interaction can also be determined by analysis of the
three-dimensional structure as determined by such techniques as
nuclear magnetic resonance analysis, crystallography or
photoaffinity labelling (see, e.g., de Vos et al., 1992,
Science 255: 306-312; Smith at al., 1992, Journal of Molecular
Biology 224: 899-904; Wlodaver et al., 1992, FEES Letters 309:
59-64).
The present invention also relates to isolated nucleic
acid sequences encoding a polypeptide of the present invention,
which hybridize under very low stringency conditions,
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 17 -
preferably low stringency conditions, more preferably medium
stringency conditions, more preferably medium-high stringency
conditions, even more preferably high stringency conditions,
and most preferably very high stringency conditions with a
nucleic acid probe which hybridizes under the same conditions
with the nucleic acid sequence of SEQ ID NO:1 or its
complementary strand; or allelic variants and subsequences
thereof (Sambrook et a/., 1989, supra), as defined herein.
The present invention also relates to isolated nucleic
acid sequences produced by (a) hybridizing a DNA under very
low, low, medium, medium-high, high, or very high stringency
conditions with (i) the nucleotides of SEQ ID NO:1, (ii) the
cDNA sequence contained in the nucleotides of SEQ ID NO:1,
(iii) a subsequence of (i) or (ii), or (iv) a complementary
strand of (i), (ii), or (iii); and (b) isolating the nucleic
acid sequence. The subsequence is preferably a sequence of at
least 100 nucleotides such as a sequence which encodes a
polypeptide fragment which has branching enzyme activity.
Methods for Producing Mutant Nucleic Acid Sequences
The present invention further relates to methods for
producing a mutant nucleic acid sequence, comprising
introducing at least one mutation into the polypeptide coding
sequence of SEQ ID NO:1 or a subsequence thereof, wherein the
mutant nucleic acid sequence encodes a polypeptide which
consists of the amino acid sequence of SEQ ID NO:2 or a
fragment thereof which has branching enzyme activity.
The introduction of a mutation into the nucleic acid
sequence to exchange one nucleotide for another nucleotide may
be accomplished by site-directed mutagenesis using any of the
methods known in the art. Particularly useful is the procedure
which utilizes a supercoiled, double stranded DNA vector with
an insert of interest and two synthetic primers containing the
desired mutation. The oligonucleotide primers, each
complementary to opposite strands of the vector, extend during
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 18 -
temperature cycling by means of Pfu DNA polymerase . On
incorporation of the primers, a mutated plasmid containing
staggered nicks is generated. Following temperature cycling,
the product is treated with DpnI which is specific for
methylated and hemimethylated DNA to digest the parental DNA
template and to select for mutation-containing synthesized DNA.
Other procedures known in the art may also be used.
Nucleic Acid Constructs
The present invention also relates to nucleic acid
constructs comprising a nucleic acid sequence of the present
invention operably linked to one or more control sequences
which direct the expression of the coding sequence in a
suitable host cell under conditions compatible with the control
sequences. Expression will be understood to include any step
involved in the production of the polypeptide including, but
not limited to, transcription,
post-transcriptional
modification, translation, post-translational modification, and
secretion.
"Nucleic acid construct" is defined herein as a nucleic
acid molecule, either single- or double-stranded, which is
isolated from a naturally occurring gene or which has been
modified to contain segments of nucleic acid combined and
juxtaposed in a manner that would not otherwise exist in
nature. The term nucleic acid construct is synonymous with the
term expression cassette when the nucleic acid construct
contains all the control sequences required for expression of a
coding sequence of the present invention. The term "coding
sequence" is defined herein as a nucleic acid sequence which
directly specifies the amino acid sequence of its protein
product. The boundaries of the coding sequence are generally
determined by a ribosome binding site (prokaryotes) or by the
ATG start codon (eukaryotes) located just upstream of the open
reading frame at the 5' end of the mRNA and a transcription
terminator sequence located just downstream of the open reading
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 19 -
frame at the 3' end of the mRNA. A coding sequence can include,
but is not limited to, DNA, cDNA, and recombinant nucleic acid
sequences.
An isolated nucleic acid sequence encoding a polypeptide
of the present invention may be manipulated in a variety of
ways to provide for expression of the polypeptide. Manipulation
of the nucleic acid sequence prior to its insertion into a
vector may be desirable or necessary depending on the
expression vector. The techniques for modifying nucleic acid
sequences utilizing recombinant DNA methods are well known in
the art.
The term "control sequences" is defined herein to include
all components which are necessary or advantageous for the
expression of a polypeptide of the present invention. Each
control sequence may be native or foreign to the nucleic acid
sequence encoding the polypeptide. Such control sequences
include, but are not limited to, a leader, polyadenylation
sequence, propeptide sequence, promoter, signal peptide
sequence, and transcription terminator. At a minimum, the
control sequences include a promoter, and transcriptional and
translational stop signals. The control sequences may be
provided with linkers for the purpose of introducing specific
restriction sites facilitating ligation of the control
sequences with the coding region of the nucleic acid sequence
encoding a polypeptide. The term "operably linked" is defined
herein as a configuration in which a control sequence is
appropriately placed at a position relative to the coding
sequence of the DNA sequence such that the control sequence
directs the expression of a polypeptide.
The control sequence may be an appropriate promoter
sequence, a nucleic acid sequence which is recognized by a host
cell for expression of the nucleic acid sequence. The promoter
sequence contains transcriptional control sequences which
mediate the expression of the polypeptide. The promoter may be
any nucleic acid sequence which shows transcriptional activity
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 20 -
in the host cell of choice including mutant, truncated, and
hybrid promoters, and may be obtained from genes encoding
extracellular or intracellular polypeptides either homologous
or heterologous to the host cell.
Examples of suitable promoters for directing the
transcription of the nucleic acid constructs of the present
invention, especially in a bacterial host cell, are the
promoters obtained from the E. coli lac operon, Streptomyces
coelicolor agarase gene (dagA), Bacillus subtilis levansucrase
gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL),
Bacillus stearothermophilus maltogenic amylase gene (amylk1),
Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus
licheniformis penicillinase gene (penP), Bacillus subtilis xylA
and xylB genes, and prokaryotic beta-lactamase gene (Villa-
Kamaroff et al., 1978, Proceedings of the National Academy of
Sciences USA 75: 3727-3731), as well as the tac promoter
(DeBoer et al., 1983, Proceedings of the National Academy of
Sciences USA 80: 21-25). Further promoters are described in
"Useful proteins from recombinant bacteria" in Scientific
American, 1980, 242: 74-94; and in Sambrook et al., 1989,
supra.
Examples of suitable promoters for directing the
transcription of the nucleic acid constructs of the present
invention in a filamentous fungal host cell are promoters
obtained from the genes for Aspergillus oryzae TAKA amylase,
Rhizomucor miehei aspartic proteinase, Aspergillus niger
neutral alpha-amylase, Aspergillus niger acid stable alpha-
amylase, Aspergillus niger or Aspergillus awamori glucoamylase
(glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline
protease, Aspergillus oryzae triose phosphate isomerase,
Aspergillus nidulans acetamidase, and Fusarium oxysporum
trypsin-like protease (WO 96/00787), as well as the NA2-tpi
promoter (a hybrid of the promoters from the genes for
Aspergillus niger neutral alpha-amylase and Aspergillus oryzae
triose phosphate isomerase), and mutant, truncated, and hybrid
CA 02367999 2001-09-14
W000/58445
PCT/DK00/00152
- 21 -
promoters thereof.
In a yeast host, useful promoters are obtained from the
genes for Saccharomyces cerevisiae enolase (ENO-1),
Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces
cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate
dehydrogenase (ADH2/GAP), and Saccharomyces cerevisiae 3-
phosphoglycerate kinase. Other useful promoters for yeast host
cells are described by Romanos et al., 1992, Yeast 8: 423-488.
The control sequence may also be a suitable transcription
terminator sequence, a sequence recognized by a host cell to
terminate transcription. The terminator sequence is operably
\ linked to the 3' terminus of the nucleic acid sequence encoding
the polypeptide. Any terminator which is functional in the host
cell of choice may be used in the present invention.
Preferred terminators for filamentous fungal host cells
are obtained from the genes for Aspergillus oryzae TAKA
amylase, Aspergillus niger glucoamylase, Aspergillus nidulans
anthranilate synthase, Aspergillus niger alpha-glucosidase, and
Fusarium oxysporum trypsin-like protease.
Preferred terminators for yeast host cells are obtained
from the genes for Saccharomyces cerevisiae enolase,
Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces
cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other
useful terminators for yeast host cells are described by
Romanos et al., 1992, supra.
The control sequence may also be a suitable leader
sequence, a nontranslated region of an mRNA which is important
for translation by the host cell. The leader sequence is
operably linked to the 5' terminus of the nucleic acid sequence
encoding the polypeptide. Any leader sequence that is
functional in the host cell of choice may be used in the
present invention.
Preferred leaders for filamentous fungal host cells are
obtained from the genes for Aspergillus oryzae TAKA amylase and
Aspergillus nidulans triose phosphate isomerase.
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 22 -
Suitable leaders for yeast host cells are obtained from
the genes for Saccharomyces cerevisiae enolase (ENO-1),
Saccharomyces cerevisiae 3-phosphoglycerate
kinase,
Saccharomyces cerevisiae alpha-factor, and Saccharomyces
cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate
dehydrogenase (ADH2/GAP).
The control sequence may also be a polyadenylation
sequence, a sequence operably linked to the 3' terminus of the
nucleic acid sequence and which, when transcribed, is
recognized by the host cell as a signal to add polyadenosine
residues to transcribed mRNA. Any polyadenylation sequence
which is functional in the host cell of choice may be used in
the present invention.
Preferred polyadenylation sequences for filamentous fungal
host cells are obtained from the genes for Aspergillus oryzae
TAKA amylase, Aspergillus niger glucoamylase, Aspergillus
nidulans anthranilate synthase, Fusarium oxysporum trypsin-like
protease, and Aspergillus niger alpha-glucosidase.
Useful polyadenylation sequences for yeast host cells are
described by Guo and Sherman, 1995, Molecular Cellular Biology
15: 5983-5990.
The control sequence may also be a signal peptide coding
region that codes for an amino acid sequence linked to the
amino terminus of a polypeptide and directs the encoded
polypeptide into the cell's secretory pathway. The 5' end of
the coding sequence of the nucleic acid sequence may inherently
contain a signal peptide coding region naturally linked in
translation reading frame with the segment of the coding region
which encodes the secreted polypeptide. Alternatively, the 5'
end of the coding sequence may contain a signal peptide coding
region which is foreign to the coding sequence. The foreign
signal peptide coding region may be required where the coding
sequence does not naturally contain a signal peptide coding
region. Alternatively, the foreign signal peptide coding region
may simply replace the natural signal peptide coding region in
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 23 -
order to enhance secretion of the polypeptide. However, any
signal peptide coding region which directs the expressed
polypeptide into the secretory pathway of a host cell of choice
may be used in the present invention.
Effective signal peptide coding regions for bacterial host
cells are the signal peptide coding regions obtained from the
genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus
stearothermophilus alpha-amylase, Bacillus licheniformis
subtilisin, Bacillus licheniformis beta-lactamase, Bacillus
stearothermophilus neutral proteases (nprT, nprS, nprM), and
Bacillus subtilis prsA. Further signal peptides are described
by Simonen and Palva, 1993, Microbiological Reviews 57: 109-
137.
Effective signal peptide coding regions for filamentous
fungal host cells are the signal peptide coding regions
obtained from the genes for Aspergillus oryzae TAKA amylase,
Aspergillus niger neutral amylase, Aspergillus niger
glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola
insolens cellulase, and Humicola lanuginosa lipase.
Useful signal peptides for yeast host cells are obtained
from the genes for Saccharomyces cerevisiae alpha-factor and
Saccharomyces cerevisiae invertase. Other useful signal peptide
coding regions are described by Romanos et al., 1992, supra.
The control sequence may also be a propeptide coding
region that codes for an amino acid sequence positioned at the
amino terminus of a polypeptide. The resultant polypeptide is
known as a proenzyme or propolypeptide (or a zymogen in some
cases). A propolypeptide is generally inactive and can be
converted to a mature active polypeptide by catalytic or
autocatalytic cleavage of the propeptide from the
propolypeptide. The propeptide coding region may be obtained
from the genes for Bacillus subtilis alkaline protease (aprE),
Bacillus subtilis neutral protease (nprT), Saccharomyces
cerevisiae alpha-factor, Rhizomucor miehei aspartic proteinase,
and Myceliophthora thermophila laccase (WO 95/33836).
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 24 -
Where both signal peptide and propeptide regions are
present at the amino terminus of a polypeptide, the propeptide
region is positioned next to the amino terminus of a
polypeptide and the signal peptide region is positioned next to
the amino terminus of the propeptide region.
It may also be desirable to add regulatory sequences which
allow the regulation of the expression of the polypeptide
relative to the growth of the host cell. Examples of regulatory
systems are those which cause the expression of the gene to be
turned on or off in response to a chemical or physical
stimulus, including the presence of a regulatory compound.
Regulatory systems in prokaryotic systems include the lac, tac,
and trp operator systems. In yeast, the ADH2 system or GAL1
system may be used. In filamentous fungi, the TAKA alpha-
amylase promoter, Aspergillus niger glucoamylase promoter, and
Aspergillus oryzae glucoamylase promoter may be used as
regulatory sequences. Other examples of regulatory sequences
are those which allow for gene amplification. In eukaryotic
systems, these include the dihydrofolate reductase gene which
is amplified in the presence of methotrexate, and the
metallothionein genes which are amplified with heavy metals. In
these cases, the nucleic acid sequence encoding the polypeptide
would be operably linked with the regulatory sequence.
Expression Vectors
The present invention also relates to recombinant
expression vectors comprising a nucleic acid sequence of the
present invention, a promoter, and transcriptional and
translational stop signals. The various nucleic acid and
control sequences described above may be joined together to
produce a recombinant expression vector which may include one
or more convenient restriction sites to allow for insertion or
substitution of the nucleic acid sequence encoding the
polypeptide at such sites. Alternatively, the nucleic acid
sequence of the present invention may be expressed by inserting
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 25 -
the nucleic acid sequence or a nucleic acid construct
comprising the sequence into an appropriate vector for
expression. In creating the expression vector, the coding
sequence is located in the vector so that the coding sequence
is operably linked with the appropriate control sequences for
expression.
The recombinant expression vector may be any vector (e.g.,
a plasmid or virus) which can be conveniently subjected to
recombinant DNA procedures and can bring about the expression
of the nucleic acid sequence. The choice of the vector will
typically depend on the compatibility of the vector with the
host cell into which the vector is to be introduced. The
vectors may be linear or closed circular plasmids.
The vector may be an autonomously replicating vector,
i.e., a vector which exists as an extrachromosomal entity, the
replication of which is independent of chromosomal replication,
e.g., a plasmid, an extrachromosomal element, a minichromosome,
or an artificial chromosome. The vector may contain any means
for assuring self-replication. Alternatively, the vector may be
one which, when introduced into the host cell, is integrated
into the genome and replicated together with the chromosome(s)
into which it has been integrated. Furthermore, a single vector
or plasmid or two or more vectors or plasmids which together
contain the total DNA to be introduced into the genome of the
host cell, or a transposon may be used.
The vectors of the present invention preferably contain
one or more selectable markers which permit easy selection of
transformed cells. A selectable marker is a gene the product of
which provides for biocide or viral resistance, resistance to
heavy metals, prototrophy to auxotrophs, and the like. Examples
of bacterial selectable markers are the dal genes from Bacillus
subtilis or Bacillus licheniformis, or markers which confer
antibiotic resistance such as ampicillin, kanamycin,
chloramphenicol or tetracycline resistance. Suitable markers
for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1,
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 26 -
and URA3. Selectable markers for use in a filamentous fungal
host cell include, but are not limited to, amdS (acetamidase),
argB (ornithine carbamoyltransferase), bar (phosphinothricin
acetyltransferase), hygB (hygromycin phosphotransferase), niaD
(nitrate reductase), pyrG
(orotidine-5'-phosphate
decarboxylase), sC (sulfate adenyltransferase),
trpC
(anthranilate synthase), as well as equivalents thereof.
Preferred for use in an Aspergillus cell are the amdS and pyrG
genes of Aspergillus nidulans or Aspergillus oryzae and the bar
gene of Streptomyces hygroscopicus.
The vectors of the present invention preferably contain an
element(s) that permits stable integration of the vector into
the host cell's genome or autonomous replication of the vector
in the cell independent of the genome.
For integration into the host cell genome, the vector may
rely on the nucleic acid sequence encoding the polypeptide or
any other element of the vector for stable integration of the
vector into the genome by homologous or nonhomologous
recombination. Alternatively, the vector may contain additional
nucleic acid sequences for directing integration by homologous
recombination into the genome of the host cell. The additional
nucleic acid sequences enable the vector to be integrated into
the host cell genome at a precise location(s) in the
chromosome(s). To increase the likelihood of integration at a
precise location, the integrational elements should preferably
contain a sufficient number of nucleic acids, such as 100 to
1,500 base pairs, preferably 400 to 1,500 base pairs, and most
preferably 800 to 1,500 base pairs, which are highly homologous
with the corresponding target sequence to enhance the
probability of homologous recombination. The integrational
elements may be any sequence that is homologous with the target
sequence in the genome of the host cell. Furthermore, the
integrational elements may be non-encoding or encoding nucleic
acid sequences. On the other hand, the vector may be integrated
into the genome of the host cell by non-homologous
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 27 -
recombination.
For autonomous replication, the vector may further
comprise an origin of replication enabling the vector to
replicate autonomously in the host cell in question. Examples
of bacterial origins of replication are the origins of
replication of plasmids pBR322, pUC19, pACYC177, and pACYC184
permitting replication in E. coli, and pUB110, pE194, pTA1060,
and pAM81 permitting replication in Bacillus. Examples of
origins of replication for use in a yeast host cell are the 2
micron origin of replication, ARS1, ARS4, the combination of
ARS1 and CEN3, and the combination of ARS4 and CEN6. The origin
of replication may be one having a mutation which makes its
functioning temperature-sensitive in the host cell (see, e.g.,
Ehrlich, 1978, Proceedings of the National Academy of Sciences
USA 75: 1433).
More than one copy of a nucleic acid sequence of the
present invention may be inserted into the host cell to
increase production of the gene product. An increase in the
copy number of the nucleic acid sequence can be obtained by
integrating at least one additional copy of the sequence into
the host cell genome or by including an amplifiable selectable
marker gene with the nucleic acid sequence where cells
containing amplified copies of the selectable marker gene, and
thereby additional copies of the nucleic acid sequence, can be
selected for by cultivating the cells in the presence of the
appropriate selectable agent.
The procedures used to ligate the elements described above
to construct the recombinant expression vectors of the present
invention are well known to one skilled in the art (see, e.g.,
Sambrook et al., 1989, supra).
Host Cells
The present invention also relates to recombinant host
cells, comprising a nucleic acid sequence of the invention,
which are advantageously used in the recombinant production of
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 28 -
the polypeptides. A vector comprising a nucleic acid sequence
of the present invention is introduced into a host cell so that
the vector is maintained as a chromosomal integrant or as a
self-replicating extra-chromosomal vector as described earlier.
The term "host cell" encompasses any progeny of a parent cell
that is not identical to the parent cell due to mutations that
occur during replication. The choice of a host cell will to a
large extent depend upon the gene encoding the polypeptide and
its source.
The host cell may be a unicellular microorganism, e.g., a
prokaryote, or a non-unicellular microorganism, e.g., a
eukaryote.
Useful unicellular cells are bacterial cells such as gram
positive bacteria including, but not limited to, a Bacillus
cell, e.g., Bacillus alkalophilus, Bacillus amyloliquefaciens,
Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus
coagulans, Bacillus lautus, Bacillus lentus, Bacillus
licheniformis, Bacillus megaterium,
Bacillus
stearothermophilus, Bacillus subtilis, and
Bacillus
thuringiensis; or a Streptomyces cell, e.g., Streptomyces
lividans or Streptomyces murinus, or gram negative bacteria
such as E. coli and Pseudomonas sp. In a preferred embodiment,
the bacterial host cell is a Bacillus lentus, Bacillus
licheniformis, Bacillus stearothermophilus, or Bacillus
subtilis cell. In another preferred embodiment, the Bacillus
cell is an alkalophilic Bacillus.
The introduction of a vector into a bacterial host cell
may, for instance, be effected by protoplast transformation
(17, 17-.1'157antgarsingl ::rhnepneft2:79c 1979, Molecular Gzeraly:zetia:
Spizizin, 1961, Journal of Bacteriology 81: 823-829, or Dubnau
and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:
209-221), electroporation (see, e.g., Shigekawa and Dower,
1988, Biotechniques 6: 742-751), or conjugation (see, e.g.,
Koehler and Thorne, 1987, Journal of Bacteriology 169: 5771-
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 29 -
5278).
The host cell may be a eukaryote, such as a mammalian,
insect, plant, or fungal cell.
In a preferred embodiment, the host cell is a fungal cell.
"Fungi" as used herein includes the phyla Ascomycota,
Basidiomycota, Chytridiomycota, and Zygomycota (as defined by
Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The
Fungi, 8th edition, 1995, CAB International, University Press,
Cambridge, UK) as well as the Oomycota (as cited in Hawksworth
et al., 1995, supra, page 171) and all mitosporic fungi
(Hawksworth et a/., 1995, supra).
In a more preferred embodiment, the fungal host cell is a
yeast cell. "Yeast" as used herein includes ascosporogenous
yeast (Endomycetales), basidiosporogenous yeast, and yeast
belonging to the Fungi Imperfecti (Blastomycetes). Since the
classification of yeast may change in the future, for the
purposes of this invention, yeast shall be defined as described
in Biology and Activities of Yeast (Skinner, F.A., Passmore,
S.M., and Davenport, R.R., eds, Soc. App. Bacteriol. Symposium
Series No. 9, 1980).
In an even more preferred embodiment, the yeast host cell
is a Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces,
Schizosaccharomyces, or Yarrowia cell.
In a most preferred embodiment, the yeast host cell is a
Saccharomyces carlsbergensis, Saccharomyces cerevisiae,
Saccharomyces diastaticus, Saccharomyces
douglasii,
Saccharomyces kluyveri, Saccharomyces norbensis
or
Saccharomyces oviformis cell. In another most preferred
embodiment, the yeast host cell is a Kluyveromyces lactis cell.
In another most preferred embodiment, the yeast host cell is a
Yarrowia lipolytica cell.
In another more preferred embodiment, the fungal host cell
is a filamentous fungal cell. "Filamentous fungi" include all
filamentous forms of the subdivision Eumycota and Oomycota (as
defined by Hawksworth et al., 1995, supra). The filamentous
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 30 -
fungi are characterized by a mycelial wall composed of chitin,
cellulose, glucan, chitosan, mannan, and other complex
polysaccharides. Vegetative growth is by hyphal elongation and
carbon catabolism is obligately aerobic. In contrast,
vegetative growth by yeasts such as Saccharomyces cerevisiae is
by budding of a unicellular thallus and carbon catabolism may
be fermentative.
In an even more preferred embodiment, the filamentous
fungal host cell is a cell of a species of, but not limited to,
Acremonium, Aspergillus, Fusarium, Humicola, Mucor,
Myceliophthora, Neurospora, Penicillium,
Thielavia,
Tolypocladium, or Trichoderma.
In a most preferred embodiment, the filamentous fungal
host cell is an Aspergillus awamori, Aspergillus foetidus,
Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger
or Aspergillus oryzae cell. In another most preferred
embodiment, the filamentous fungal host cell is a Fusarium
bactridioides, Fusarium cerealis, Fusarium crookwellense,
Fusarium culmorum, Fusarium graminearum, Fusarium graminum,
Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum,
Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum,
Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium
sulphureum, Fusarium torulosum, Fusarium trichothecioides, or
Fusarium venenatum cell. In an even most preferred embodiment,
the filamentous fungal parent cell is a Fusarium venenatum
(Nirenberg sp. nov.) cell. In another most preferred
embodiment, the filamentous fungal host cell is a Humicola
insol ens, Humicola lanuginosa, Mucor miehei, Myceliophthora
thermophila, Neurospora crassa, Penicillium purpurogenum,
Thielavia terrestris, Trichoderma harzianum, Trichoderma
koningii, Trichoderma longibrachiatum, Trichoderma reesei, or
Trichoderma viride cell.
Fungal cells may be transformed by a process involving
protoplast formation, transformation of the protoplasts, and
regeneration of the cell wall in a manner known per se.
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 31 -
Suitable procedures for transformation of Aspergillus host
cells are described in EP 238 023 and Yelton et al., 1984,
Proceedings of the National Academy of Sciences USA 81: 1470-
1474. Suitable methods for transforming Fusarium species are
described by Malardier et al., 1989, Gene 78: 147-156 and WO
96/00787. Yeast may be transformed using the procedures
described by Becker and Guarente, In Abelson, J.N. and Simon,
M.I., editors, Guide to Yeast Genetics and Molecular Biology,
Methods in Enzymology, Volume 194, pp 182-187, Academic Press,
Inc., New York; Ito et al., 1983, Journal of Bacteriology 153:
163; and Hinnen et al., 1978, Proceedings of the National
Academy of Sciences USA 75: 1920.
Methods of Production
The present invention also relates to methods for
producing a polypeptide of the present invention comprising (a)
cultivating a strain, which in its wild-type form is capable of
producing the polypeptide; and (b) recovering the polypeptide.
Preferably, the strain is of the genus Rhodothermus, and more
preferably Rhodothermus obamensis.
The present invention also relates to methods for
producing a polypeptide of the present invention comprising (a)
cultivating a host cell under conditions conducive for
production of the polypeptide; and (b) recovering the
polypeptide.
The present invention also relates to methods for
producing a polypeptide of the present invention comprising (a)
cultivating a host cell under conditions conducive for
production of the polypeptide, wherein the host cell comprises
a mutant nucleic acid sequence having at least one mutation in
the polypeptide coding region of SEQ ID NO:1, wherein the
mutant nucleic acid sequence encodes a polypeptide which
consists of the amino acids of SEQ ID NO:2, and (b) recovering
the polypeptide.
In the production methods of the present invention, the
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 32 -
cells are cultivated in a nutrient medium suitable for
production of the polypeptide using methods known in the art.
For example, the cell may be cultivated by shake flask
cultivation, small-scale or large-scale fermentation (including
continuous, batch, fed-batch, or solid state fermentations) in
laboratory or industrial fermentors performed in a suitable
medium and under conditions allowing the polypeptide to be
expressed and/or isolated. The cultivation takes place in a
suitable nutrient medium comprising carbon and nitrogen sources
and inorganic salts, using procedures known in the art.
Suitable media are available from commercial suppliers or may
be prepared according to published compositions (e.g., in
catalogues of the American Type Culture Collection). If the
polypeptide is secreted into the nutrient medium, the
polypeptide can be recovered directly from the medium. If the
polypeptide is not secreted, it can be recovered from cell
lysates.
The polypeptides may be detected using methods known in
the art that are specific for the polypeptides. These detection
methods may include use of specific antibodies, formation of an
enzyme product, or disappearance of an enzyme substrate. For
example, an enzyme assay may be used to determine the activity
of the polypeptide as described herein.
The resulting polypeptide may be recovered by methods
known in the art. For example, the polypeptide may be recovered
from the nutrient medium by conventional procedures including,
but not limited to, centrifugation, filtration, extraction,
spray-drying, evaporation, or precipitation.
The polypeptides of the present invention may be purified
by a variety of procedures known in the art including, but not
limited to, chromatography (e.g., ion exchange, affinity,
hydrophobic, chromatofocusing, and size
exclusion),
electrophoretic procedures (e.g., preparative isoelectric
focusing), differential solubility (e.g., ammonium sulfate
precipitation), SDS-PAGE, or extraction (see, e.g., Protein
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 33 -
Purification, J.-C. Janson and Lars Ryden, editors, VCH
Publishers, New York, 1989).
Plants
The present invention also relates to a transgenic plant,
plant part, or plant cell which has been transformed with a
nucleic acid sequence encoding a polypeptide having branching
enzyme activity of the present invention so as to express and
produce the polypeptide in recoverable quantities. The
polypeptide may be recovered from the plant or plant part.
Alternatively, the plant or plant part containing the
recombinant polypeptide may be used as such for improving the
quality of a food or feed, e.g., improving nutritional value,
palatability, and rheological properties, or to destroy an
antinutritive factor.
The transgenic plant can be dicotyledonous (a dicot) or
monocotyledonous (a monocot). Examples of monocot plants are
grasses, such as meadow grass (blue grass, Poa), forage grass
such as festuca, lolium, temperate grass, such as Agrostis, and
cereals, e.g., wheat, oats, rye, barley, rice, sorghum, and
maize (corn).
Examples of dicot plants are tobacco, legumes, such as
lupins, potato, sugar beet, pea, bean and soybean, and
cruciferous plants (family Brassicaceae), such as cauliflower,
rape seed, and the closely related model organism Arabidopsis
thaliana.
Examples of plant parts are stem, callus, leaves, root,
fruits, seeds, and tubers. Also specific plant tissues, such as
chloroplast, apoplast, mitochondria, vacuole, peroxisomes, and
cytoplasm are considered to be a plant part. Furthermore, any
plant cell, whatever the tissue origin, is considered to be a
plant part.
Also included within the scope of the present invention
are the progeny of such plants, plant parts and plant cells.
The transgenic plant or plant cell expressing a
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 34 -
polypeptide of the present invention may be constructed in
accordance with methods known in the art. Briefly, the plant or
plant cell is constructed by incorporating one or more
expression constructs encoding a polypeptide of the present
invention into the plant host genome and propagating the
resulting modified plant or plant cell into a transgenic plant
or plant cell.
Conveniently, the expression construct is a nucleic acid
construct which comprises a nucleic acid sequence encoding a
polypeptide of the present invention operably linked with
appropriate regulatory sequences required for expression of the
nucleic acid sequence in the plant or plant part of choice.
Furthermore, the expression construct may comprise a selectable
marker useful for identifying host cells into which the
expression construct has been integrated and DNA sequences
necessary for introduction of the construct into the plant in
question (the latter depends on the DNA introduction method to
be used).
The choice of regulatory sequences, such as promoter and
terminator sequences and optionally signal or transit sequences
is determined, for example, on the basis of when, where, and
how the polypeptide is desired to be expressed. For instance,
the expression of the gene encoding a polypeptide of the
present invention may be constitutive or inducible, or may be
developmental, stage or tissue specific, and the gene product
may be targeted to a specific tissue or plant part such as
seeds or leaves. Regulatory sequences are, for example,
described by Tague et al., 1988, Plant Physiology 86: 506.
For constitutive expression, the 35S-CaMV promoter may be
used (Franck et al., 1980, Cell 21: 285-294). Organ-specific
promoters may be, for example, a promoter from storage sink
tissues such as seeds, potato tubers, and fruits (Edwards &
Coruzzi, 1990, Ann. Rev. Genet. 24: 275-303), or from metabolic
sink tissues such as meristems (Ito et al., 1994, Plant Mol.
Biol. 24: 863-878), a seed specific promoter such as the
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 35 -
glutelin, prolamin, globulin, or albumin promoter from rice (Wu
et al., 1998, Plant and Cell Physiology 39: 885-889), a Vicia
faba promoter from the legumin B4 and the unknown seed protein
gene from Vicia faba (Conrad et al., 1998, Journal of Plant
Physiology 152: 708-711), a promoter from a seed oil body
protein (Chen et al., 1998, Plant and Cell Physiology 39: 935-
941), the storage protein napA promoter from Brassica napus, or
any other seed specific promoter known in the art, e.g., as
described in WO 91/14772. Furthermore, the promoter may be a
leaf specific promoter such as the rbcs promoter from rice or
tomato (Kyozuka at al., 1993, Plant Physiology 102: 991-1000,
the chlorella virus adenine methyltransferase gene promoter
(Mitra and Higgins, 1994, Plant Molecular Biology 26: 85-93),
or the aldP gene promoter from rice (Kagaya et a/., 1995,
Molecular and General Genetics 248: 668-674), or a wound
inducible promoter such as the potato pin2 promoter (Xu et al.,
1993, Plant Molecular Biology 22: 573-588).
A promoter enhancer element may also be used to achieve
higher expression of the enzyme in the plant. For instance, the
promoter enhancer element may be an intron which is placed
between the promoter and the nucleotide sequence encoding a
polypeptide of the present invention. For instance, Xu at al.,
1993, supra disclose the use of the first intron of the rice
actin 1 gene to enhance expression.
The selectable marker gene and any other parts of the
expression construct may be chosen from those available in the
art.
The nucleic acid construct is incorporated into the plant
genome according to conventional techniques known in the art,
including Agrobacterium-mediated transformation, virus-mediated
transformation, microinjection, particle bombardment, biolistic
transformation, and electroporation (Gasser at al., 1990,
Science 244: 1293; Potrykus, 1990, Bio/Technology 8: 535;
Shimamoto at al., 1989, Nature 338: 274).
Presently, Agrobacterium tumefaciens-mediated gene
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 36 -
transfer is the method of choice for generating transgenic
dicots (for a review, see Hooykas and Schilperoort, 1992, Plant
Molecular Biology 19: 15-38). However it can also be used for
transforming monocots, although other transformation methods
are generally preferred for these plants. Presently, the method
of choice for generating transgenic monocots is particle
bombardment (microscopic gold or tungsten particles coated with
the transforming DNA) of embryonic calli or developing embryos
(Christou, 1992, Plant Journal 2: 275-281; Shimamoto, 1994,
Current Opinion Biotechnology 5: 158-162; Vasil et al., 1992,
Bio/Technology 10: 667-674). An alternative method for
transformation of monocots is based on protoplast
transformation as described by Omirulleh et al., 1993, Plant
Molecular Biology 21: 415-428.
Following transformation, the transformants having
incorporated therein the expression construct are selected and
regenerated into whole plants according to methods well-known
in the art.
The present invention also relates to methods for
producing a polypeptide of the present invention comprising (a)
cultivating a transgenic plant or a plant cell comprising a
nucleic acid sequence encoding a polypeptide having branching
enzyme activity of the present invention under conditions
conducive for production of the polypeptide; and (b) recovering
the polypeptide.
Compositions
In a still further aspect, the present invention relates
to compositions comprising a polypeptide of the present
invention. Preferably, the compositions are enriched in a
polypeptide of the present invention. In the present context,
the term "enriched" indicates that the branching enzyme
activity of the composition has been increased, e.g., with an
enrichment factor of 1.1.
The composition may comprise a polypeptide of the
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 37 -
invention as the major enzymatic component, e.g., a mono-
component composition. Alternatively, the composition may
comprise multiple enzymatic activities, such as an
aminopeptidase, amylase, carbohydrase,
carboxypeptidase,
catalase, cellulase, chitinase, cutinase, cyclodextrin
glycosyltransferase, deoxyribonuclease, esterase,
alpha-
galactosidase, beta-galactosidase,
glucoamylase, alpha-
glucosidase, beta-glucosidase, haloperoxidase, invertase,
laccase, lipase, mannosidase, oxidase, pectinolytic enzyme,
peptidoglutaminase, peroxidase, phytase, polyphenoloxidase,
proteolytic enzyme, ribonuclease, transglutaminase, or
xylanase.
The polypeptide compositions may be prepared in accordance
with methods known in the art and may be in the form of a
liquid or a dry composition. For instance, the polypeptide
composition may be in the form of a granulate or a
microgranulate. The polypeptide to be included in the
composition may be stabilized in accordance with methods known
in the art.
Examples are given below of preferred uses of the
polypeptide compositions of the invention. The dosage of the
polypeptide composition of the invention and other conditions
under which the composition is used may be determined on the
basis of methods known in the art.
Detergent Compositions
The branching enzymes of the invention may be added to
and thus become a component of a detergent composition.
The detergent composition of the invention may for
example be formulated as a hand or machine laundry detergent
composition including a laundry additive composition suitable
for pre-treatment of stained fabrics and a rinse added fabric
softener composition, or be formulated as a detergent
composition for use in general household hard surface cleaning
operations, or be formulated for hand or machine dishwashing
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 38 -
operations.
In a specific aspect, the invention provides a detergent
additive comprising the branching enzymes of the invention. The
detergent additive as well as the detergent composition may
comprise one or more other enzymes such as a protease, a lipase,
a cutinase, an amylase, a carbohydrase, a cellulase, a
pectinase, a mannanase, an arabinase, a galactanase, a xylanase,
an oxidase, e.g., a laccase, and/or a peroxidase.
In general the properties of the chosen enzyme(s) should
be compatible with the selected detergent, (i.e. pH-optimum,
compatibility with other enzymatic and non-enzymatic
ingredients, etc.), and the enzyme(s) should be present in
effective amounts.
Proteases: Suitable proteases include those of animal,
vegetable or microbial origin. Microbial origin is preferred.
Chemically modified or protein engineered mutants are included.
The protease may be a serine protease or a metallo protease,
preferably an alkaline microbial protease or a trypsin-like
protease. Examples of alkaline proteases are subtilisins;
especially those derived from Bacillus, e.g., subtilisin Novo,
subtilisin Carlsberg, subtilisin 309, subtilisin 147 and
subtilisin 168 (described in WO 89/06279). Examples of trypsin-
like proteases are trypsin (e.g. of porcine or bovine origin)
and the Fusarium protease described in WO 89/06270 and WO
94/25583.
Examples of useful proteases are the variants described
in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946,
especially the variants with substitutions in one or more of
the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120,
123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.
Preferred commercially available protease enzymes include
AlcalaseTM, SavinaseTM, PrimaseTM, DuralaseTM, EsperaseTM, and
KannaseTM (Novo Nordisk A/S), MaxataseTM, MaxacalTM, MaxapemTM,
ProperaseTM, PurafectTM, Purafect axPTM, FN2TM, and FN3TM
(Genencor International Inc.).
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 39 -
Lipases: Suitable lipases include those of bacterial or fungal
origin. Chemically modified or protein engineered mutants are
included. Examples of useful lipases include lipases from
Humicola (synonym Thermomyces), e.g. from H. lanuginosa (T.
lanuginosus) as described in EP 258 068 and EP 305 216 or from
H. insolens as described in WO 96/13580, a Pseudomonas lipase,
e.g. from P. alcaligenes or P. pseudoalcaligenes (EP 218 272),
P. cepacia (EP 331 376), P. stutzeri (GB 1,372,034), P.
fluorescens, Pseudomonas sp. strain SD 705 (WO 95/06720 and WO
96/27002), P. wisconsinensis (WO 96/12012), a Bacillus lipase,
e.g. from B. subtilis (Dartois et al. (1993), Biochemica et
Biophysica Acta, 1131, 253-360), B. stearothermophilus (JP
64/744992) or B. pumilus (WO 91/16422).
Other examples are lipase variants such as those
described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105,
WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO
95/14783, WO 95/22615, WO 97/04079 and WO 97/07202.
Preferred commercially available lipase enzymes include
LipolaseTM, Lipolase UltraTM and LipomaxTM (Novo Nordisk A/S).
Amylases: Suitable amylases (a and/or p) include those of bac-
terial or fungal origin. Chemically modified or protein
engineered mutants are included. Amylases include, for example,
a-amylases obtained from Bacillus, e.g. a special strain of B.
licheniformis, described in more detail in GB 1,296,839.
Examples of useful amylases are the variants described in
WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424,
especially the variants with substitutions in one or more of
the following positions: 15, 23, 105, 106, 124, 128, 133, 154,
156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305,
391, 408, and 444.
Commercially available amylases are DuramylTM, TermamylTm,
FungamylTM and BANTM (Novo Nordisk A/S), RapidaseTM and
PurastarTM (from Genencor International Inc.).
Cellulases: Suitable cellulases include those of bacterial or
fungal origin. Chemically modified or protein engineered
CA 02367999 2001-09-14
W000/58445
PCT/DK00/00152
- 40 -
mutants are included. Suitable cellulases include cellulases
from the genera Bacillus, Pseudomonas, Humicola, Fusarium,
Thielavia, Acremonium, e.g. the fungal cellulases produced from
Humicola insol ens, Myceliophthora therm ophila and Fusarium
oxysporum disclosed in US 4,435,307, US 5,648,263, US
5,691,178, US 5,776,757 and WO 89/09259.
Especially suitable cellulases are the alkaline or
neutral cellulases having colour care benefits. Examples of
such cellulases are cellulases described in EP 0 495 257, EP 0
531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples
are cellulase variants such as those described in WO 94/07998,
EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO
95/24471, WO 98/12307 and PCT/DK98/00299.
Commercially available cellulases include CelluzymeTM,
and CarezymeTM (Novo Nordisk A/S), ClazinaseTM, and Puradax HATM
(Genencor International Inc.), and KAC_500(B)TM
(Kao
Corporation).
Peroxidases/Oxidases: Suitable peroxidases/oxidases include
those of plant, bacterial or fungal origin. Chemically modified
or protein engineered mutants are included. Examples of useful
peroxidases include peroxidases from Coprinus, e.g. from C.
cinereus, and variants thereof as those described in WO
93/24618, WO 95/10602, and WO 98/15257.
Commercially available peroxidases include GuardzymeTM
(Novo Nordisk A/S).
The detergent enzyme(s) may be included in a detergent
composition by adding separate additives containing one or more
enzymes, or by adding a combined additive comprising all of
these enzymes. A detergent additive of the invention, i.e. a
separate additive or a combined additive, can be formulated e.g.
as a granulate, a liquid, a slurry, etc. Preferred detergent
additive formulations are granulates, in particular non-dusting
granulates, liquids, in particular stabilized liquids, or slur-
ries.
Non-dusting granulates may be produced, e.g., as
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 41 -
disclosed in US 4,106,991 and 4,661,452 and may optionally be
coated by methods known in the art. Examples of waxy coating
materials are poly(ethylene oxide) products (polyethyleneglycol,
PEG) with mean molar weights of 1000 to 20000; ethoxylated
nonylphenols having from 16 to 50 ethylene oxide units;
ethoxylated fatty alcohols in which the alcohol contains from 12
to 20 carbon atoms and in which there are 15 to 80 ethylene
oxide units; fatty alcohols; fatty acids; and mono- and di- and
triglycerides of fatty acids. Examples of film-forming coating
materials suitable for application by fluid bed techniques are
given in GB 1483591. Liquid enzyme preparations may, for in-
stance, be stabilized by adding a polyol such as propylene
glycol, a sugar or sugar alcohol, lactic acid or boric acid
according to established methods. Protected enzymes may be
prepared according to the method disclosed in EP 238,216.
The detergent composition of the invention may be in any
convenient form, e.g., a bar, a tablet, a powder, a granule, a
paste or a liquid. A liquid detergent may be aqueous, typically
containing up to 70 % water and 0-30 % organic solvent, or non-
aqueous.
The detergent composition comprises one or more surfac-
tants, which may be non-ionic including semi-polar and/or
anionic and/or cationic and/or zwitterionic. The surfactants are
typically present at a level of from 0.1% to 60% by weight.
When included therein the detergent will usually contain
from about 1% to about 40% of an anionic surfactant such as
linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl
sulfate (fatty alcohol sulfate), alcohol ethoxysulfate,
secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester,
alkyl- or alkenylsuccinic acid or soap.
When included therein the detergent will usually contain
from about 0.2% to about 40% of a non-ionic surfactant such as
alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside,
alkyldimethylamineoxide, ethoxylated fatty acid monoethanol-
amide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 42 -
amide, Or N-acyl N-alkyl derivatives of glucosamine
("glucamides").
The detergent may contain 0-65 % of a detergent builder
or complexing agent such as zeolite, diphosphate, triphosphate,
phosphonate, carbonate, citrate, nitrilotriacetic acid,
ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic
acid, alkyl- or alkenylsuccinic acid, soluble silicates or
layered silicates (e.g. SKS-6 from Hoechst).
The detergent may comprise one or more polymers.
Examples are carboxymethylcellulose, poly(vinylpyrrolidone),
poly (ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-
N-oxide), poly(vinylimidazole), polycarboxylates such as
polyacrylates, maleic/acrylic acid copolymers and lauryl
methacrylate/acrylic acid copolymers.
The detergent may contain a bleaching system, which may
comprise a H202 source such as perborate or percarbonate, which
may be combined with a peracid-forming bleach activator such as
tetraacetylethylenediamine or
nonanoyloxybenzenesulfonate.
Alternatively, the bleaching system may comprise peroxyacids of
e.g. the amide, imide, or sulfone type.
The enzyme(s) of the detergent composition of the inven-
tion may be stabilized using conventional stabilizing agents,
e.g., a polyol such as propylene glycol or glycerol, a sugar or
sugar alcohol, lactic acid, boric acid, or a boric acid
derivative, e.g., an aromatic borate ester, or a phenyl boronic
acid derivative such as 4-formylphenyl boronic acid, and the
composition may be formulated as described in e.g. WO 92/19709
and WO 92/19708.
The detergent may also contain other conventional
detergent ingredients such as e.g. fabric conditioners including
clays, foam boosters, suds suppressors, anti-corrosion agents,
soil-suspending agents, anti-soil redeposition agents, dyes,
bactericides, optical brighteners, hydrotropes, tarnish
inhibitors, or perfumes.
It is at present contemplated that in the detergent
CA 02367999 2008-11-03
- 43 -
-
compositions any enzyme, in particular the branching enzymes of
the invention, may be added in an amount corresponding to 0.01-
100 mg of enzyme protein per liter of wash liqour, preferably
0.05-5 mg of enzyme protein per liter of wash liqour, in
particular 0.1-1 mg of enzyme protein per liter of wash liqour.
The branching enzymes of the invention may additionally be
incorporated in the detergent formulations disclosed in WO
97/07202,
Uses
The present invention is also directed to methods for
using the polypeptides having branching enzyme activity. For
instance, the polypeptides of the invention may be used for
modification of starch or starch containing materials so as to
improve the properties of such materials.
Examples of materials that can be modified with BE include
native starch (unmodified) of all types (potato, maize, wheat),
waxy starches, high amylose starches, amylose, amylopectin,
chemically modified starches including dextrins, -converted
starch, crosslinked starch (di-starch phosphate), starch ethers
and starch esters (starch acetate, hydroxyalkylated starch,
octenyl-succinate starch).
The BE of the invention is useful for modification of a
starch-like material, as described above, to make the modified
material better suited for its intended purpose, e.g. in the
preparation of food products as described in US 4 454 161, e.g.
food and drink compositions, food additive compositions,
pharmaceutical preparations, sizing agents, adhesives etc.
Normally starch materials modified with BE has a high
solubility, low viscosity and less tendency to retrograde
compared to unmodified starch. These properties can be used to
improve the properties of food products prepared from the
starch-like material, especially the storage stability of such
products. Examples of food products are: bread, desserts,
cakes, snacks, noodles and pasta, baby food, sport drinks,
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 44 -
processed foods that are frozen or stored cold and pet foods.
Enzymatical modification can be performed either on a starch-
like material separately before addition to the food product or
by adding the enzyme to the food material before or just after
cooking, making the modification directly in the food.
For surface sizing and coating of paper high solubility,
low viscosity and good stability of the used starch solutions
are very important making BE modified starch relevant for these
applications as shown in EP 0 690 170.
The present invention is further described by the
following examples, which should not be construed as limiting
the scope of the invention.
EXAMPLE 1
Materials and Methods
Rhodothermus obamensis (JCM 9785) was obtained from Japan
Collection of Microorganisms, The Institute of Physical and
Chemical Research, Wako, Saitama 351-0198, Japan.
Molecular cloning techniques are described in J. Sambrook,
E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning, A
Laboratory Manual, 2nd edition, Cold Spring Harbor, New York.
The following commercial plasmids/vectors were used:
pT7Blue (Invitrogen, Netherlands)
pBluescript SK(-) (Stratagene, U.S.A.)
pBAD/Myc-HisA (Invitrogen, Netherlands).
The following strains were used for transformation and
protein expression:
TOP10 E. coli (Invitrogen, Netherlands)
E. coil DH12S (GIBCO BRL, Life Technologies, U.S.A.)
SB growth medium (DIFCO #0123-17-3) is composed of:
trypton/pepton, 32 g/1;
yeast extract, 20 g/1;
NaC1, 5 g/1;
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 45 -
5N NaOH, 1 m1/1.
Chemicals used as buffers and substrates were commercial
products of at least reagent grade.
Branching enzyme activity
BE activity was determined according to a modified version
of the procedure described by Takata et al., Applied and
Environmental Microbiology (1994), p. 3097 (assay A):
50 pl enzyme solution is mixed with 50 pl substrate solution
and incubated for 30 min at testing temperature. The substrate
solution is 0.1% type III amylose dissolved in 0.1 M Tris
buffer. The reaction is terminated by the addition of 2 ml of
iodine reagent. Iodine reagent is made daily from 0.5 ml of
stock solution (0.26 g of 12 and 2.6 g of KI in 10 ml of water)
mixed with 0.5 ml of 1 N HC1 and diluted to 130 ml. The mixture
is incubated for 15 minutes at room temperature to stabilize
the color. Activity is measured as difference in A660 between a
tested sample and a control in which cell extract is replaced
by water. One unit of branching enzyme activity is defined as
the amount of enzyme that can decrease the A660 of the amylose-
iodine complex by 1% per minute at 60 C, pH 7Ø
Preparation of a R. obamensis glgB probe
Primers a) (SEQ ID NO:3) and b) (SEQ ID NO:4) were
designed (based on alignment of reported bacterial glgB
sequences), prepared and used in a polymerase chain reaction
(PCR) with genomic DNA from Rhodothermus obamensis.
SEQ ID NO:3, PCR primer a) (forward):
5'-GAGCACCCCYTCGACGGCAGTTGG-3'
SEQ ID NO:4, PCR primer b) (reverse):
5'-CATCCAICCWAKRTTCCA-3'
I = inosine
CA 02367999 2008-11-03
- 46 -
K = G or T
R = A or G
W = A or T
Y = C or T
Reaction components were mixed [genomic DNA, 0.1 ng/pl;
dNTPs 0.125 mM each; Me, 2.5 mM; primer, 2 pM each; Tag
polymerase 0.025 U/pl in lx buffer (Roche Diagnostics, Japan)]
and submitted for PCR under the following conditions:
Step Temperature Time
1 94 C 5 minutes
2 50 C 45 seconds
3 72 C 1 minute
4 94 C 45 seconds
5 50 C 45 seconds
6 72 C 1 minute
7 4 C forever
Table 1. Step 4 to step 6 were repeated 30 times.
The PCR reaction mixture was separated on an agarose gel,
and the expected.size of the amplified g1gB PCR fragments was
calculated from E. co1i g1gB sequence data, resulting in
approx. 580 bp. These fragments were gel-purified with QIAquick
(QIAGEN, Japan), and then ligated into a pT7Blue vector using
Takara ligation kit ver. 2 (Takara, Japan). The ligation
mixture was purified with phenol/chloroform, and then
transformed into E. coli DH12S by electroporation. The plasmid
(pMSra8) from the obtained transformant was checked by
restriction enzyme digestion to confirm the size of the
Rhodothermus obamensis g1gB insert.
Cloning of R. obamensis glgB gene
Using the inserted fragment of pMSra8 as a R. obamensis
g1gB probe, Southern hybridization was performed on digested
*Trade-mark
CA 02367999 2008-11-03
- 47 -
genomic DNA from R. obamensis to select convenient restriction
enzymes for generating subclones. A hybridized BamHI fragment
of 3.5-kb was selected for a glgB subclone. Therefore, R.
obamensis genomic DNA was digested with BamHI, and the size-
fractionated DNA was cut out from agarose gels and cloned into
pBluescript SK(-). The BamHI sub-library was made by
transforming the ligated clones into E. coil DH12S cells.
Colony lift was performed on transformants of the BamHI sub-
library using Hybond-W*membranes (Amersham Pharmacia Biotech,
Japan), and then hybridized to the DIG-labeled R. obamensis
g1qB probe. Positive colonies were picked and inserts were
checked by PCR. Plasmids from selected colonies were prepared
and sequenced revealing that the 3.5 kb BamHI fragment were
missing the 5'-terminal of g1gB (pMSral0). Accordingly another
1.5 sub-library made from R. obamensis genomic DNA double-digested
with B7pnI and SalI was screened with the R. obamensis glgB
probe to recover the 5'-terminal of R. obamensis g1gB
(pMSra29). The whole sequence of structural glgB was obtained
from pMSra10 and pMSra29, and PCR primers (SEQ ID NO:5 and SEQ
ID NO:6) for amplification of the whole glgB gene was designed
from this sequence.
Construction of expression vectors
By using primers c) (SEQ ID NO:5) and d) (SEQ ID NO:6)
which include respectively a BspHI and a HindIII restriction
enzyme site, the whole g1gB gene was PCR-amplified from
Rhodothermus obamensis genomic DNA (to avoid mutations during
the PCR reaction Expand High Fidelity from Boehringer Mannheim
was used). Cutting the PCR-amplified fragment with BspHI and
HindIII allowed directionally cloning into a pBAD/Myc-HisA
vector digested with Ncol and HindIII. The resulting vector
pMSra33 produced R. obamensis BE after transformation in TOP10
E. coli and induction with arabinose.
= 35 SEQ ID NO:5, Primer c); PCR primer (forward)-for amplification
*Trade-mark
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 48 -
of the Rhodothermus obamensis glgB gene. Underlined nucleotides
introduce the BspHI site:
5'-TTCCTCATGAGCTGGCTCACGGAAGAAGACA-3'
SEQ ID NO:6, Primer d); PCR primer (reverse) for amplification
of the Rhodothermus obamensis glgB gene. Underlined nucleotides
introduce the HindIII site:
5'-GTTTAAAGCTTTTCAGGACGGCTACC-3'
Biological deposit DSM 12607
Plasmid pT7Blue with the complete Rhodothermus obamensis
glgB gene (SEQ ID NO:1) was also transformed in E. coli DH12S,
which was deposited at DSMZ as DSM 12607 (described in Deposit
of Biological Material).
Protein expression
R. obamensis BE was heterologously expressed in TOP10 E.
coli strain transformed with pMSra33. The E. coli cells were
incubated in SB medium with 100 pg/m1 ampicillin at 28 C
overnight. 0.0002% arabinose was added for induction of
expression. Cells were spinned down by centrifugation and
resuspended in 20 mM phosphate buffer (pH 6.0). The amount of
buffer corresponded to 1/20 of growth media. Cells were then
sonicated and debris was removed by centrifugation.
Removing endogenous amylolytic activity from E. coli
By removing all endogenous amylolytic activity from the E.
coli extract, it becomes possible to use the iodine method
(Takata et al., Applied and Environmental Microbiology (1994),
p. 3097) to detect expressed BE activity. Accordingly it was
tested if heat-treatment could be used to eliminate endogenous
amylolytic activity from the host E. coli strain with the
pBAD/Myc-HisA vector and no glgB insert (negative control). The
results showed that a 60 C/20 min. treatment was enough to
heat-kill background amylolytic activity measured with the
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 49 -
amylose-iodine assay described by Takata et al., where there
was no activity detected.
Partial purification of R.obamensis BE variant Y397C+L419P
Sequencing of an expressed R. obamensis BE reveiled that
two changes compared to the mature amino acid sequence of SEQ
ID NO:2 had been introduced during the PCR process:
a) Tyr397 was changed to Cys397
b) Leu419 was changed to Pro419.
This BE variant is hereinafter denoted "Y397C+L419P".
R.obamensis BE with the substitutions Y397C+L419P
expressed in E.coli was partially purified by ion-exchange and
hydroxyapatite column chromatography. Heat treated cell extract
was dialyzed and applied to Super-Q Toyopeal (22 mm x 200 mm,
TOSOH), then eluted with linear gradient of 0 to 0.6 M NaC1 in
50 mM potassium phosphate buffer (pH 7.4). The fractions that
had branching enzyme activity were collected and applied to
Macro-prep Ceramic Hydroxyapatite Type I (14 mm x 100 mm,
BioRad), then eluted with gradient of 5 to 400 mM sodium
phosphate (pH 6.5). Fractions showing activity were collected.
It showed one major band with a couple of minor bands on SDS-
PAGE with Coomassie brilliant blue strain.
Branching linkage formation
The formation of a-1,6-branching linkage was confirmed by
the modified version of branching linkage assay (BL assay,
Takeda et al., Carbohydrate Research, 240 253-260 (1993)). The
used substrate was 0.5% type III amylose (Sigma) dissolved in
100 mM Tris-HC1 (pH 7.5). The substrate (90 pl) and enzyme
solution (10 pl) was mixed and incubated at 60 C for 30
minutes, then the reaction was terminated by boiling for 4
minutes. After addition of 10 pl of 1 M acetate buffer pH 4.1,
either 5 pl of isoamylase (1 mg/ml, Hayashibara Co.Ltd.) or 5
pl of deionized water was added to the reaction mixture. It was
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 50 -
incubated at 45 C for 45 minutes. The reaction solution was
then added 460 pl of ice-cold ethanol and kept on ice for 10
minutes. Precipitated saccharides were harvested by
centrifugation at 12,000 rpm for 5 minutes and vacuum dried
once, then dissolved again in 8 pl of 1N NaOH and 292 pl of
deionized water. Reducing power of the solution was measured by
using the modified 3,5-dinitrosalycylic acid (DNS) method
(Luchsinger and Cornesky, 1962). DNS solution was prepared by
dissolving 0.05 g of 3,5-dinitrosalycylic acid in 10 ml of 2N
NaOH at first, then 3 g of Rochelle salt was added to the
solution, and finally total volume was adjusted to 15 ml with
deionized water. Sample solution (0.2-0.3 ml) was mixed with
0.4 ml of DNS solution and boiled for 5 minutes. After cooling
with running water, 1.8 ml of water was added to the reaction
mixture and absorbance at 525 nm was measured. The amount of
reducing ends was estimated as equivalent to glucose amount.
Partially purified sample of Y397C+L419P was used for the
measurement of branching linkage formation. As shown in table
5, reducing ends were produced with the isoamylase treatment,
that indicated a-1,6-branching linkage was formed by
Y397C+L419P.
Experiment number Isoamylase Reducing ends
treatment (pmol)
Exp. 1 0.43
none 0
Exp. 2 0.17
none 0.04
Table 2.
EXAMPLE 2
Effect of temperature and pH for BE variant Y397C+L419P
The temperature and pH optima were evaluated for BE
variant Y397C+L419P (described in Example 1).
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2001-09-14
W000/58445
PCT/DK00/00152
- 51 -
The assay used for BE activity measurement was performed
as described in Materials and Methods. To avoid endogenous
amylolytic activity from E. coli expressing the R. obamensis
BE, the cell extracts were pre-heated to 60 C for at least 20
minutes and debris was removed by centrifugation. The pre-
heated cell extract was then submitted for assays and analyzed
for BE activity.
In the pH optimum assay, different buffers were used to
prepare substrate solutions:
pH < 4 0.1 M sodium citrate
4 < pH < 6 0.1 M sodium acetate
6 < pH < 10 0.1 M Tris
pH > 10 0.1 M glysylglycine.
The enzyme (Y397C+L419P) was incubated at the indicated
temperature for 30 minutes at pH 7Ø Branching enzyme activity
was measured as described above. The experiments were performed
at least in triplicate; mean values and std. deviations are
shown in table 2 and table 3 below.
The data show the optimum temperature of Y397C+L419P to be
around 65 C.
Temperature ( C) Relative activity (%)
Y397C+L419P
39 +/- 4
61 +/- 3
64 +/- 8
93 +/- 4
93 +/- 4
97 +/- 3
68 94 +/- 4
78 +/- 3
72 57 +/- 2
54 +/- 7
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 52 -
80 12 +/- 6
90 9 +/- 3
Table 3.
Temperature ( C) Remaining activity (%)
Y397C+L419P
60 99 +/- 1
65 100 +/- 0
70 103 +/- 3
75 82 +/- 1
80 2 +/- 3
85 2 +/- 3
90 ND
Table 4.
The pH activity experiments were done at 60 C, and the
enzyme was incubated for 30 minutes. The experiments were
performed at least in triplicate; mean values and std.
deviations are shown in table 4 below. The data indicate that
Y397C+L419P has a broad pH optimum of about pH 5 to about pH 8.
pH Relative activity (%)
Y397C+L419P
5.3 43 +/- 3
6.3 91 +/- 1
6.7 98 +/- 3
7.6 73 +/- 3
9.0 21 +/- 1
9.3 15 +/- 2
Table 5.
EXAMPLE 3
lE Cyclo dextrin preparation by BE variant Y397C+L419P
Rice amylopectin (Motyl B, Shimada Chemical, Japan) was
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
- 53 -
treated with R.obamensis BE with the substitutions Y397C+L419P
(described in Example 1) (400 units/g starch) in Tris-HC1
buffer (pH 7) at 50 C for 18 hours. After removing debris by
centrifugation at 15,000 rpm for 10 minutes, 2 volumes of
ethanol was added to the solution and precipitated dextrin was
recovered and dried. About 67 g of dextrin was obtained from
100 g of rice amylopectin. If intramolecular branching linkage
has occurred by enzyme treatment, cyclic dextrin cnat is
tolerant to glucoamylase should be obtained. One gram of above
mentioned dextrin was treated with 1500 units of glucoamylase
(Rhizopus sp. Wako Pure Chemicals, Japan) at pH 4.1, 40 C for
18 hours, and the resulting dextrin was recovered by ethanol.
About 200 mg of dextrin was obtained. There was no dextrin
obtained with the treatment in presence of acid a-amylase.
Glucoamylase resistant dextrin was treated again with only
glucoamylase (0.9 units/g dextrin) or in the combination of
glucoamylase and isoamylase (0.9 units and 29 units per g
dextrin, respectively) at pH 4.5, 40 C for 16 hours. As the
result, 90% of dextrin was recovered with glucoamylase solely,
while only 10% dextrin remained after the treatment in the
presence of isoamylase. It indicated that the cyclic dextrin
was formed by intramolecular a-1,6-branching linkage catalyzed
by Y397C+L419P.
EXAMPLE 4
Expression of R.obamensis BE in Aspergillus
Host organism
Aspergillus oryzae BECh2 is described in Danish patent
application PA 1999 01726. It is a mutant of JaL228 (described
in W098/123000), which is a mutant of IF04177.
Transformation of A.oryzae
Aspergillus oryzae strain BECh2 was inoculated in 100 ml
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
- 54 -
of YPG medium and incubated at 32 C for 16 hours with stirring
at 80 rpm. Grown mycelia was collected by filtration followed
by washing with 0.6 M KC1 and re-suspended in 30 ml of 0.6 M
KC1 containing Glucanex (available from Novo Nordisk) at the
concentration of 30 p1/mi. The mixture was incubated at 32 C
with the agitation at 60 rpm until protoplasts were formed.
After filtration to remove the remained mycelia, protoplasts
were collected by centrifugation and washed with STC buffer
twice. The protoplasts were counted with a hematitometer and
re-suspended in a solution of STC:STPC:DMSO (8:2:0.1) to a
final concentration of 1.2 x 107 protoplasts/ml. About 4 pg of
DNA was added to 100 pl of protoplast solution, mixed gently
and incubated on ice for 30 minutes. 1 pl STPC buffer was added
to the mixture and incubated at 37 C for another 30 minutes.
After the addition of 10 ml of Cove top agarose pre-warmed at
50 C, the reaction mixture was poured onto COVE agar plates.
The plates were incubated at 32 C for 5 days or until
transformants appeared.
Media and buffer solution
COVE: per liter 342.3 g sucrose, 20 ml COVE salt solution, 10
mM acetamide, 15 mM CsC12, 30 g Agar noble (Difco)
COVE salt solution: per liter 26 g KC1, 26 g MgSO4-7H20, 76 g
KH2PO4, 50m1 Cove trace metals.
Cove trace metals: per liter 0.04 g NaB407-10H20, 0.4 g CuSO4-
5H20, 1.2 g FeSO4-7H20, 0.7 g MnSO4-H20, 0.7 g Na2Mo02-2H20, 0.7
g ZnSO4-7H20.
AMG trace metals: per liter 14.3 g ZnSO4-7H20, 2.5 g CuSO4-5H20,
0.5 g N1C12, 13.8 g FeSO4, 8.5 g MnSO4, 3.0 g citric acid.
YPG: per liter 4 g yeast extract, 1 g KH2PO4, 0.5 g MgSO4-7H20,
5 g glucose, pH 6Ø
STC: 0.8 M Sorbitol, 25 mM Tris pH 8, 25 mM CaCl2.
STPC: 40% PEG4000 in STC buffer.
Cove top agarose: per liter 342.3 g sucrose, 20 ml COVE salt
solution, 10 mM Acetamide, 10 g low melt agarose.
CA 02367999 2008-11-03
- 55 -
- MS-9: per liter 30 g soybean powder, 20 g glycerol, pH 6Ø
MDU-2Bp: per liter 45 g maltose-1H20, 7 g yeast extract, 12 g
KH2PO4, 1 g MgSO4-7H20, 2 g K2SO4, 5 g Urea, 1 g NaC1, 0.5 ml AMG
trace metal solution pH 5Ø
SDS-PAGE and western blotting
= SDS polyacrylamide electrophoresis was carried out using
the commercialized gel PAGEL AE6000 NPU-7.5L (7.5T%) with the
apparatus AE-6400 (Atto, Japan) following the provided
protocol. Separated protein in a gel was transferred to a Clear
Blot* membrane-P AE-6665 (Atto, Japan) using AE-6677 Horizon
blot (Atto, Japan). Detection of the protein was employed with
Immuno Blot Assay Kit (BioRad).
Construction of expression plasmids of R.obamensis glgB for
Asperglilus
R.obamensis glgB gene was amplified from R.obamensis
genomic DNA using the primers sets of a) & b), or a) & c) to
introduce the restriction enzyme site BglII and noI at each
end. Primer c) gives the sequence of c-myc epitope comprising
Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu at the C-terminal glgB.
a) 5'-GAAGATCTAT GAGCTGGCTC ACGGAAGAAG ACATCCGGCG CTGGGAAA-3'
b) 5'-CCGCTCGAGC TACCCGTGCT CCGGCTCCAG GATGAGGGCG GCCA-3'
c) 5'-CCGCTCGAGC TACAGGTCCT CTTCGGAGAT GAGCTTCTGC TCCCCGTGCT
CCGGCTCCAG GATGAGGGCG GCCA-3'
Reaction components, i.e. 40 ng of chromosome DNA of
R.obamensis, 300 pmol of each primer, 0.2 mM of dNTPs and 2.6
units of DNA polymerase of Expandm High Fidelity PCR system
(Boehringer), were mixed in the provided buffer and submitted
for PCR under the following conditions.
Step Temperature Time
1 94 C 2 mins
*Trade-mark
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 56 -
2 94 C 15 sec
3 55 C 30 sec
4 72 C 90 sec
94 C 15 sec
6 55 C 30 sec
7 72 C 90 + 20 sec / cycle
8 72 C 7 mins
Table 6. Step 2 to step 4 were repeated 10 times, and step 5 to
step 7 were repeated 20 cycles.
The amplified 1.9 Kb fragment was purified with QIA gel
5 extraction kit (Qiagen) and after digestion with BglII and
XhoI, it was ligated into pCaHj483 digested with BamHI and
XhoI. The plasmid pCaHj483 has Aspergillus niger neutral
amylase promoter, Aspergillus nidulans TPI leader sequence,
Aspergillus niger glucoamylase terminator and Aspergillus
nidulans amdS gene as a marker. The plasmid obtained with the
primer set a) & b) was termed pIH28 and the one obtained with
the primer set of a) & c) was designated pIH29.
Expression of R.obamensis glgB in A.oryzae
The expression plasmids, pIH28 and pI1-129, were digested
with NotI and resulting 6 kb fragments containing the
expression cassette of R.obamensis glgB were purified with QIA
gel extraction kit. A.oryzae BECh2 was transformed with each
fragment and selection positive transformants were isolated.
Transformant was inoculated to 100 ml of MS-9 in 500 ml of
shaking flask and cultivated at 32 C for 1 day and 3 ml of each
culture was transferred to 100 ml of MDU-25p in shaking flask
to cultivate at 32 C for 2-3 days. Grown cells were harvested
by centrifugation at 3500 rpm for 15 minutes. About 0.1 g of
collected cells was suspended in 100 pl of 2x conc. of sample
loading buffer (100 mM Tris-HC1 (pH 6.8), 200 mM
Dithiothreitol, 4% SDS, 0.2% Bromophenol blue and 20% glycerol)
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2001-09-14
W000/58445
PCT/DK00/00152
- 57 -
and boiled for 5 minutes. After centrifugation at 14000 rpm for
minutes, 10 pl of supernatant was applied to a polyacrylamide
gel, and subjected for electrophoresis in the running buffer
(25 mM Tris, 0.1% SDS, 192 mM Glycine) at 20 mA per gel.
5 Resulting gel was stained with Coomassie brilliant blue.
Positive transformants showed the protein band of expected size
of R.obamensis glgB, 72 kDa. The gel applied with the extract
of transformant with c-myc tag was subjected for western
blotting using Anti-myc antibody (Invitrogen) as primary
antibody and Anti-mouse IgG (Sigma) as secondary antibody.
Positive signals were obtained at the position corresponding to
72 kDa.
EXAMPLE 5
R.obamensis BE assay and effect of temperature and pH
To inactivate endogenous amylase activity from host
strain, the cell extract was heated at 65 C for 30 minutes.
Activity was measured as described before.
The pH activity profile was measured at 65 C and the
temperature activity profile was obtained at pH 7. The
experiments were performed either in duplicate or in triplet
and the means and standard deviations are shown below.
Temperature stability was measured on the R.obamensis BE
without c-myc tag as follows; enzyme solution containing 30-50
units/m1 (pH 7) was incubated at the different temperatures for
minutes, and then remaining branching enzyme activity was
measured.
The data indicate the optimum pH and optimum temperature
30 of R.obamensis BE to be around pH 7 and 65 C, respectively. The
presence of c-myc tag did not affect the pH and temperature
profile.
pH Relative activity (%) Relative activity (%)
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 58 -
BE1-5 BBe28
(w/o myc-tag) (with tag)
2.4 8 +/- 1 6 +/- 2
3.0 '7 +/- 2 7 +/- 2
4.0 10 +/- 1 8 +/- 1
5.2 74 +/- 8 67 +/- 1
6.3 87 +/- 2 77 +/- 5
7.1 97 +/- 1 97 +/- 3
7.8 93 +/- 1 89 +/- 4
8.6 88 +/- 1 81 +/- 1
9.5 83 +/- 4 75 +/- 1
10.6 12 +/- 2 16 +/- 1
Table 7.
Temperature Relative activity (%) Relative activity (%)
( C) BE1-5 BBe28
(w/o myc-tag) (with tag)
30 4 +/- 1 1 +/- 4
40 11 +/- 1 6 +/- 1
50 35 +/- 1 24 +/- 0
55 60 +/- 5 50 +/- 0
60 80 +/- 1 71 +/- 1
63 92 +/- 3 88 +/- 2
65 96 +/- 4 94 +/- 4
68 93 +/- 3 90 +/- 4
70 87 +/- 2 86 +/- 1
73 75 +/- 1 73 +/- 2
75 59 +/- 5 59 +/- 2
80 17 +/- 1 12 +/- 2
Table 8.
Temperature ( C) Remaining activity (%)
R.obamensis BE
60 95 +/- 5
SUBSTITUTESHEET(RULE26)
CA 02367999 2001-09-14
WO 00/58445
PCT/DK00/00152
- 59 -
65 95 +/- 5
70 88 +/- 3
75 91 +/- 3
80 91 +/- 2
85 83 +/- 1
90 13 +/- 3
Table 9.
SUBSTITUTE SHEET (RULE 26)
CA 02367999 2008-11-03
- 60 -
Deposit of Biological Material
An E. coli clone containing the BE gene from Rhodothermus
obamensis inserted into plasmid pT7Blue (see Example 1) has
been deposited under the terms of the Budapest Treaty with the
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
(DSMZ). Mascheroder Weg lb, D-38124 Braunschweig, Germany, and
=
given the following accession number:
Deposit Accession Number Date of Deposit
NN049443 DSM 12607 1998-Dec-23
The strain has been deposited under conditions that assure
that access to the culture will be available during the
pendency of this patent application to one determined by the
Commissioner of Patents and Trademarks to be entitled thereto
under 37 C.F.R. 1.14 and 35 U.S.C. 122. The deposit
represents a substantially pure culture of the deposited
strain. The deposit is available as required by foreign patent
laws in countries wherein counterparts of the subject
application, or its progeny are filed. However, it should be
understood that the availability of a deposit does not
constitute a license to practice the subject invention in
derogation of patent rights granted by governmental action.
The invention described and claimed herein is not to be
limited in scope by the specific embodiments herein disclosed,
since these embodiments are intended as illustrations of
several aspects of =the invention. Any equivalent embodiments
are intended to be within the scope of this invention. Indeed,
various modifications of the invention in addition to those
shown and described herein will become apparent to those
skilled in the art from the foregoing description. Such
modifications are also intended to fall within the scope of the
appended claims. In the case of conflict, the present
disclosure including definitions will control.
CA 02367999 2001-09-14
VA) 00/58445 PCT/DK00/00152
Sequence listing
<110> Novo Nordisk A/S
<120> Polypeptides having branching enzyme activity and
nucleic acids encoding same
<130> Rhodothermus obamensis BE
<140>
<141>
<160> 2
<170> PatentIn Ver. 2.1
<210> 1
<211> 1866
<212> DNA
<213> Rhodothermus obamensis
<220>
<221> CDS
<222> (1)..(1866)
<220>
<221> mat peptide
<222> (4)..(1863)
<400> 1
atg ago tgg ctc acg gaa gaa gac atc cgg cgc tgg gaa ago ggt acg 48
Met Ser Trp Leu Thr Glu Glu Asp Ile Arg Arg Trp Glu Ser Gly Thr
-1 1 5 10 15
ttc tac gac agt tac cga aag ctg ggc gcc cat ccc gac gac gaa ggc 96
Phe Tyr Asp Ser Tyr Arg Lys Leu Gly Ala His Pro Asp Asp Glu Gly
20 25 30
acc tgg ttc tgc gtc tgg gcg cog cat gcc gat ggc gtc tog gtg ctc 144
Thr Trp Phe Cys Val Trp Ala Pro His Ala Asp Gly Val Ser Val Leu
35 40 45
gga gcg ttc aac gac tgg aat cog gag gcc aac cog ctg gag cgc tac 192
Gly Ala Phe Asn Asp Trp Asn Pro Glu Ala Asn Pro Leu Glu Arg Tyr
50 55 60
ggc ggc ggc ctg tgg gcc ggt tac gta cog gga gcg cgc cog ggc cac 240
Gly Gly Gly Leu Trp Ala Gly Tyr Val Pro Gly Ala Arg Pro Gly His
65 70 75
acc tac aag tat cgc atc cgg cac ggc ttc tat cag gcc gac aag acg 288
Thr Tyr Lys Tyr Arg Ile Arg His Gly Phe Tyr Gin Ala Asp Lys Thr
80 85 90 95
gat coo tac gcc ttc gcc atg gag cog cot acc ggc agt coo atc gaa 336
Asp Pro Tyr Ala Phe Ala Met Glu Pro Pro Thr Gly Ser Pro Ile Glu
100 105 110
ggg ctg OCC tcc atc atc acg cgg ctc gac tac acc tgg cac gac gac 384
Gly Leu Ala Ser Ile Ile Thr Arg Leu Asp Tyr Thr Trp His Asp Asp
115 120 125
gaa tgg atg cgg cgc cgg aag ggt cog gcc ago ctt tac gag cog gtt 432
Glu Trp Met Arg Arg Arg Lys Gly Pro Ala Ser Leu Tyr Glu Pro Val
1
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
130 135 140
tcc atc tac gag gta cat ctg ggc tcc tgg cgt cac aaa cgg ccc ggc 480
Ser Ile Tyr Glu Val His Leu Gly Ser Trp Arg His Lys Arg Pro Gly
145 150 155
gag tcc ttc tot tac cgg gag att gcc gag cog ctg gcc gac tac gtg 528
Glu Ser Phe Ser Tyr Arg Glu Ile Ala Glu Pro Leu Ala Asp Tyr Val
160 165 170 175
cag gag atg ggc ttc acg cac gtg gag ctg ctg ccc gtc atg gaa cat 576
Gin Glu Met Gly Phe Thr His Val Glu Leu Leu Pro Val Met Glu His
180 185 190
ccc tac tac ggc tcc tgg ggc tat cag gtg gtg ggc tac tac gcc cca 624
Pro Tyr Tyr Gly Ser Trp Gly Tyr Gin Val Val Gly Tyr Tyr Ala Pro
195 200 205
acg ttt cgc tac gga tca ccc cag gac ctg atg tac ctg atc gac tac 672
Thr Phe Arg Tyr Gly Ser Pro Gin Asp Leu Met Tyr Leu Ile Asp Tyr
210 215 220
ctg cac cag cgc ggc atc ggc gtc atc ctc gac tgg gtc cog ago cac 720
Leu His Gin Arg Gly Ile Gly Val Ile Leu Asp Trp Val Pro Ser His
225 230 235
ttt gcg gcc gat ccc cag gga ctg gtt ttc ttc gac ggg acc aca ctc 768
Phe Ala Ala Asp Pro Gin Gly Leu Val Phe Phe Asp Gly Thr Thr Leu
240 245 250 255
ttc gaa tac gac gat ccc aag atg cgc tat cac cot gac tgg ggt acg 816
Phe Glu Tyr Asp Asp Pro Lys Met Arg Tyr His Pro Asp Trp Gly Thr
260 265 270
tat gtg ttc gat tac aac aag cog ggc gta cgc aac ttt ctg att tcc 864
Tyr Val Phe Asp Tyr Asn Lys Pro Gly Val Arg Asn Phe Leu Ile Ser
275 280 285
aac gca ctt ttc tgg ctc gaa aag tac cac gtc gac ggg ctg cgc gtc 912
Asn Ala Leu Phe Trp Leu Glu Lys Tyr His Val Asp Gly Leu Arg Val
290 295 300
gat gcg gtg got tot atg ctc tac cgg gac tac tca cgc aag gag tgg 960
Asp Ala Val Ala Ser Met Leu Tyr Arg Asp Tyr Ser Arg Lys Glu Trp
305 310 315
aca ccc aac atc ttc ggc ggc cgt gaa aac ctg gag gcc att gat ttc 1008
Thr Pro Asn Ile Phe Gly Gly Arg Glu Asn Leu Glu Ala Ile Asp Phe
320 325 330 335
atc aag aaa ttc aac gaa acg gtc tac ctg cac ttc ccc gag gcc atg 1056
Ile Lys Lys Phe Asn Glu Thr Val Tyr Leu His Phe Pro Glu Ala Met
340 345 350
cog atc gcc gag gag tog acg gcc tgg ccc ggc gtg tog gcc ccc acc 1104
Thr Ile Ala Glu Glu Ser Thr Ala Trp Pro Gly Val Ser Ala Pro Thr
355 360 365
7.ac aac aac ggt ctg ggc ttc ctc tac aag tgg aac atg ggc tgg atg 1152
:yr Asn Asn Gly Leu Gly Phe Leu Tyr Lys Trp Asn Met Gly Trp Met
370 375 380
cac gac acg ctg gac tac atc cag cgc gat ccc atc tac cgc aag tat 1200
His Asp Thr Leu Asp Tyr Ile Gin Arg Asp Pro Ile Tyr Arg Lys Tyr
385 390 395
2
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
cac cac gac gag ctg acc ttc tcg ctc tgg tac gcc ttt tcg gag cac
1248
His His Asp Glu Leu Thr Phe Ser Leu Trp Tyr Ala Phe Ser Glu His
400 405 410 415
tac gtc ctg ccg ctc tcg cac gac gag gtg gtg cac ggc aag ggc tcg
1296
Tyr Val Leu Pro Leu Ser His Asp Glu Val Val His Gly Lys Gly Ser
420 425 430
ctc tgg ggt aaa atg ccc ggc gac gac tgg cag aag gca gcc aac ttg 1344
Leu Trp Gly Lys Met Pro Gly Asp Asp Trp Gin Lys Ala Ala Asn Leu
435 440 445
cgc ctg ctc ttt ggc cac atg tgg ggc cat ccg ggc aaa aaa ctg ctc
1392
Arg Leu Leu Phe Gly His Met Trp Gly His Pro Gly Lys Lys Leu Leu
450 455 460
ttc atg ggc ggc gag ttc ggc cag cac cac gag tgg aac cac gac acg
1440
Phe Met Gly Gly Glu Phe Gly Gin His His Glu Trp Asn His Asp Thr
465 470 475
cag ctc gaa tgg cac ctg ctg gac cag ccc tac cat cga ggt att cag
1488
Gin Leu Glu Trp His Leu Leu Asp Gin Pro Tyr His Arg Gly Ile Gin
480 485 490 495
ctg tgg gtg tgc gat ctg aac cac ctc tac cgt acg aat ccg gcc ctc
1536
Leu Trp Val Cys Asp Leu Asn His Leu Tyr Arg Thr Asn Pro Ala Leu
500 505 510
tgg cac gac gga ccg gaa ggg ttc gag tgg atc gac ttc agc gac cgc 1584
Trp His Asp Gly Pro Glu Gly Phe Glu Trp Ile Asp Phe Ser Asp Arg
515 520 525
gac cag ago gtg atc tgt tac ctg cgc aag aat gcc ggc cgc atg ctg
1632
Asp Gin Ser Val Ile Cys Tyr Leu Arg Lys Asn Ala Gly Arg Met Leu
530 535 540
ctg ttc gtg ctg aac ttt acg ccc gtg cca cgc gag cac tac cgc gtg
1680
Leu Phe Val Leu Asn Phe Thr Pro Val Pro Arg Glu His Tyr Arg Val
545 550 555
ggc gtg ccg atc ggt ggc ccc tgg cac gag gtg ctc aac ago gac gcg
1728
Gly Val Pro Ile Gly Gly Pro Trp His Glu Val Leu Asn Ser Asp Ala
560 565 570 575
gtg gcc tac ggc ggg ago ggg atg ggc aac ttc ggc cgc gtc gag gcg
1776
Val Ala Tyr Gly Gly Ser Gly Met Gly Asn Phe Gly Arg Val Glu Ala
580 585 590
gtg ccc gag too tgg cac ggc cgc ccc ttc cac tta gag ctg acg ctt 1824
Val Pro Glu Ser Trp His Gly Arg Pro Phe His Leu Glu Leu Thr Leu
595 600 605
ccc ccg ctg gcc gcc ctc atc ctg gag ccg gag cac ggg tag
1866
Pro Pro Leu Ala Ala Leu Ile Leu Glu Pro Glu His Gly
610 615 620
<210> 2
<211> 621
<212> PRT
<213> Rhodothermus obamensis
<400> 2
Met Ser Trp Leu Thr Glu Glu Asp Ile Arg Arg Trp Glu Ser Gly Thr
3
CA 02367999 2001-09-14
WO 00/58445 PCT/DK00/00152
1 5 10 15
Phe Tyr Asp Ser Tyr Arg Lys Leu Gly Ala His Pro Asp Asp Glu Gly
20 25 30
Thr Trp Phe Cys Val Trp Ala Pro His Ala Asp Gly Val Ser Val Leu
35 40 45
Gly Ala Phe Asn Asp Trp Asn Pro Glu Ala Asn Pro Leu Glu Arg Tyr
50 55 60
Gly Gly Gly Leu Trp Ala Gly Tyr Val Pro Gly Ala Arg Pro Gly His
65 70 75 80
Thr Tyr Lys Tyr Arg Ile Arg His Gly Phe Tyr Gin Ala Asp Lys Thr
85 90 95
Asp Pro Tyr Ala Phe Ala Met Glu Pro Pro Thr Gly Ser Pro Ile Glu
100 105 110
Gly Leu Ala Ser Ile Ile Thr Arg Leu Asp Tyr Thr Trp His Asp Asp
115 120 125
Glu Trp Met Arg Arg Arg Lys Gly Pro Ala Ser Leu Tyr Glu Pro Val
130 135 140
Ser Ile Tyr Glu Val His Leu Gly Ser Trp Arg His Lys Arg Pro Gly
145 150 155 160
Glu Ser Phe Ser Tyr Arg Glu Ile Ala Glu Pro Leu Ala Asp Tyr Val
165 170 175
Gin Glu Met Gly Phe Thr His Val Glu Leu Leu Pro Val Met Glu His
180 185 190
Pro Tyr Tyr Gly Ser Trp Gly Tyr Gin Val Val Gly Tyr Tyr Ala Pro
195 200 205
Thr Phe Arg Tyr Gly Ser Pro Gin Asp Leu Met Tyr Leu Ile Asp Tyr
210 215 220
Leu His Gin Arg Gly Ile Gly Val Ile Leu Asp Trp Val Pro Ser His
225 230 235 240
Phe Ala Ala Asp Pro Gin Gly Leu Val Phe Phe Asp Gly Thr Thr Leu
245 250 255
Phe Glu Tyr Asp Asp Pro Lys Met Arg Tyr His Pro Asp Trp Gly Thr
260 265 270
Tyr Val Phe Asp Tyr Asn Lys Pro Gly Val Arg Asn Phe Leu Ile Ser
275 280 285
Asn Ala Leu Phe Trp Leu Glu Lys Tyr His Val Asp Gly Leu Arg Val
290 295 300
Asp Ala Val Ala Ser Met Leu Tyr Arg Asp Tyr Ser Arg Lys Glu Trp
305 310 315 320
Thr Pro Asn Ile Phe Gly Gly Arg Glu Asn Leu Glu Ala Ile Asp Phe
325 330 335
Ile Lys Lys Phe Asn Glu Thr Val Tyr Leu His Phe Pro Glu Ala Met
340 345 350
4
CA 02367999 2001-09-14
W000/58445 PCT/DK00/00152
Thr Ile Ala Glu Glu Ser Thr Ala Trp Pro Gly Val Ser Ala Pro Thr
355 360 365
Tyr Asn Asn Gly Leu Gly Phe Leu Tyr Lys Trp Asn Met Gly Trp Met
370 375 380
His Asp Thr Leu Asp Tyr Ile Gln Arg Asp Pro Ile Tyr Arg Lys Tyr
385 390 395 400
His His Asp Glu Leu Thr Phe Ser Leu Trp Tyr Ala Phe Ser Glu His
405 410 415
Tyr Val Leu Pro Leu Ser His Asp Glu Val Val His Gly Lys Gly Ser
420 425 430
Leu Trp Gly Lys Met Pro Gly Asp Asp Trp Gin Lys Ala Ala Asn Leu
435 440 445
Arg Leu Leu Phe Gly His Met Trp Gly His Pro Gly Lys Lys Leu Leu
450 455 460
Phe Met Gly Gly Glu Phe Gly Gin His His Glu Trp Asn His Asp Thr
465 470 475 480
Gin Leu Glu Trp His Leu Leu Asp Gin Pro Tyr His Arg Gly Ile Gin
485 490 495
Leu Trp Val Cys Asp Leu Asn His Leu Tyr Arg Thr Asn Pro Ala Leu
500 505 510
Trp His Asp Gly Pro Glu Gly Phe Glu Trp Ile Asp Phe Ser Asp Arg
515 520 525
Asp Gin Ser Val Ile Cys Tyr Leu Arg Lys Asn Ala Gly Arg Met Leu
530 535 540
Leu Phe Val Leu Asn Phe Thr Pro Val Pro Arg Glu His Tyr Arg Val
545 550 555 560
Gly Val Pro Ile Gly Gly Pro Trp His Glu Val Leu Asn Ser Asp Ala
565 570 575
Val Ala Tyr Gly Gly Ser Gly Met Gly Asn Phe Gly Arg Val Glu Ala
580 585 590
Val Pro Glu Ser Trp His Gly Arg Pro Phe His Leu Glu Leu Thr Leu
595 600 605
Pro Pro Leu Ala Ala Leu Ile Leu Glu Pro Glu His Gly
610 615 620
5
